REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS, PHARMACEUTICAL COMPOSITION UNDERSTANDING

专利摘要:
reverse amide compounds as protein deacetylase inhibitors, pharmaceutical composition comprising said compounds and uses thereof. the present invention relates to new "reverse amide" compounds comprising a zinc chelating group, and the use of such compounds in the inhibition of hdac6 and in the treatment of various diseases. hdac6-related disorders or conditions.
公开号:BR112012018246B1
申请号:R112012018246-3
申请日:2011-01-21
公开日:2020-10-06
发明作者:John H. Van Duzer；Ralph Mazitschek；Walter Ogier；James Elliott Bradner；Guoxiang Huang；Dejian Xie；Nan Yu
申请人:Acetylon Pharmaceuticals, Inc；
IPC主号:

专利说明:

PRIORITY BENEFIT
[0001] This application claims the benefit of United States Provisional Application 61 / 336,460, filed on January 22, 2010, the contents of which are incorporated herein in their entirety. BACKGROUND OF THE INVENTION
[0002] The identification of small organic molecules that affect specific biological functions is an effort that impacts both biology and medicine. Such molecules are useful as therapeutic agents and as probes of biological function. Such small molecules were useful in elucidating signal transduction trails by acting as exporters of chemical protein (eliminations of chemical protein), thereby causing a loss of protein function (Schreiber and other (s), J. Am Chem, Soc, 1990, 112, 5583; Mitchison, Chem. And Biol., 1994, 1353). Additionally, due to the interaction of these small molecules with particular biological targets and their ability to affect specific biological function (eg, gene transcription), they can also serve as candidates for the development of new therapies.
[0003] A biological target of recent interest is Histone Deacetylase (HDAC) (see, for example, a debate on the use of histone deacetylase inhibitors for the treatment of cancer: Marks and other Nature Reviews cancer 2001, 7,194 ; Johnstone and other Nature Reviews Drug Discovery 2002, 287). The post-translational modification of proteins through acetylation and deacetylation of lysine residues plays a critical role in the regulation of their cellular functions. HDACs are zinc hydrolases that modulate gene expression by deacetylating N-acetyl lysine residues from histone proteins and other transcriptional regulators (Hassig and other Curr. Opin. Chem. Biol. 1997, 1, 300 -308). HDACs participate in the cell trails that control cell differentiation and shape, and an HDAC inhibitor has been shown to be effective in treating another form of recalcitrant cancer (Warrell and other J. Natl. Cancer Inst. 1998, 90, 1621- 1625). At this time, eleven human HDACs, which use Zn as a cofactor, have been identified (Taunton and other Science 1996, 272, 408-411; Yang and other J. Biol. Chem. 1997, 272, 28001- 28007 Grozinger and other Proc. Natl. Acad. Sd. USA 1999, 96, 4868-4873; Kao and other Genes Dev. 2000, 14, 55-66. Hu and other J. Biol Chem. 2000, 275, 15254-15264; Zhou and other (s) Proc. Natl. Acad. Scl USA 2001, 98, 10572-10577; Venter and other (s) Science 2001, 291, 1304-1351) these members are included in the three classes (class I, II, and IV). Seven additional HDACs have been identified that employ NAD as a cofactor. To date, no small molecule is known to selectively target any particular class or individual members of this family ((eg, ortholog-selective HDAC inhibitors have been reported: (a) Meinke and other (s) J. Med. Chem. 2000 , 14, 4919-4922; (b) Meinke, and other Curr. Med. Chem. 2001, 8, 211-235) There remains a need to structurally prepare several HDAC inhibitors and tubulin deacetylase (TDAC) particularly those that are potent and / or selective inhibitors of particular classes of HDACs or TDACs and individual HDACs and TDACs.
[0004] Recently, a cytoplasmic protein histone deacetylase, HDAC6, has been identified as necessary for the formation of agressoma and for the survival of cells after the ubiquitinated poorly duplicated protein stress. Aggression is an integral component of survival in cancer cells. The mechanism of aggression formation mediated by HDAC6 is a consequence of the catalytic activity of the carboxy terminal deacetylase domain, targeting an uncharacterized non-histone target. The present invention also provides small molecule inhibitors of HDAC6. In certain embodiments, these new compounds are potent and selective inhibitors of HDAC6.
[0005] Agressoma was first described in 1998, when it was reported that there was the appearance of perinuclear inclusion bodies associated with microtubules in cells overexpressing pathological ΔF508 alleles of the cystic fibrosis transmembrane conduction receptor (CFTR). Subsequent reports identified a pathological appearance of the agressoma with overexpressed presenilin-1 (Johnston JA, and other J Cell Biol. 1998; 143: 1883-1898), parkin (Junn E, and other J Biol Chem. 2002 ; 277: 47870-47877), peripheral myelin protein PMP22 (Notterpek L, and other Neurobiol Dis. 1999; 6: 450-460), influenza virus nucleoprotein (Anton LC, and other J Cell Biol 1999; 146: 113-124), a GFP chimera and the membrane transport protein pi 15 (Garcia-Mata R, and other J Cell Biol. 1999; 146: 1239-1254) and light chains notably amyloidogenic (Dul JL, and other J Cell Biol. 2001; 152: 705-716). Model systems were established to study (ΔF508 CFTR) ubiquitinated (Johnston JA, and other (s) J Cell Biol. 1998; 143: 1883-1898) and (GFP -250) non-ubiquitinated (Garcia-Mata R, and others (s) ) J Cell Biol. 1999; 146: 1239-1254) aggregated protein transport to the agressoma. Secretory, mutated wild-type proteins can take on unstable kinetic intermediates resulting in stable aggregates incapable of disintegration through the narrow channel of the 26S proteasome. These complexes undergo active retrograde transport by dinein to the peri-centriolar aggression, mediated in part by a cytoplasmic histone deacetylase, HDAC6 (Kawaguchi Y, and other (s) Cell. 2003; l 15: 727-738).
[0006] Histone deacetylases are a family of at least 11 zinc-binding hydrolases, which catalyze the deacetylation of lysine residues in histone proteins. Inhibition of HDAC results in chromatin hyperacetylation, changes in transcription, growth arrest and apoptosis in cancer cell lines. Early-stage clinical trials with available non-selective HDAC inhibitors demonstrate responses in hematological malignancies including multiple myeloma, although with significant toxicity. In note, synergy in vitrode with conventional chemotherapy agents (such as melphalan) with bortezomib has been reported in myeloma cell lines, however double proteasome-aggression inhibition has not been proposed. Until recently, selective HDAC inhibitors have not been performed.
[0007] HDAC6 is required for the formation of agressoma with stress of ubiquitinated protein and is essential for cellular availability in this context. HDAC6 is believed to bind ubiquitinated proteins through a zinc finger domain and to interact with the dynein motor complex through another distinct binding motif. HDAC6 has two catalytic deacetylase domains. It is currently unknown whether the histone amino terminal deacetylase or the carboxy terminal tubulin deacetylase domain (TDAC) mediates the formation of agressoma.
[0008] Abnormal protein catabolism is an indication of cancer, and is involved in the stabilization of oncogenic proteins and the degradation of tumor suppressors (Adams J. Nat Rev cancer. 2004; 4: 349-360). The tumor necrosis alpha factor induced the activation of nuclear factor cover B (NFKB) is a relevant example, mediated by the proteolytic degradation of the NFKB beta inhibitor (IKB) in malignant plasma cells. The inhibition of IKB catabolism by proteasome inhibitors explains, in part, the interruption of apoptotic growth of treated myeloma cells (Hideshima T, and other cancer (s) Res. 2001; 61: 3071-3076). Multiple myeloma is an ideal system for studying the mechanism of protein degradation in cancer. Since William Russell in 1890, cytoplasmic inclusions have been considered as a definition of the histological characteristic of malignant plasma cells. Although the precise composition of Russell bodies is not known, they are considered as ER-derived vesicles containing aggregates of monotypic immunoglobulins (Kopito RR, Sitia R. EMBO Rep. 2000; 1: 225-231) and positive stain for ubiquitin (Manetto V, and other (s) Am J Pathol. 1989; 134: 505-513). Russell's bodies have been described with overexpression of CFTR in yeast (Sullivan ML, and other J. Histochem. Cytochem. 2003; 51: 545-548), thereby raising the suspicion that these structures may be linked to catabolism of completely dominated protein, and potentially the aggressor. The role of aggression in cancer remains unclear.
[0009] The abnormal histone deacetylase activity was also linked to several neurological and neurodegenerative disorders, including stroke, Huntington's disease, amyotrophic lateral sclerosis and Alzheimer's disease. Inhibition of HDAC can induce the expression of anti-mitotic and anti-apoptotic genes, such as p21 and HSP-70, which facilitate survival. HDAC inhibitors can act on other types of neural cells in the central nervous system, such as reactive astrocytes and microglia, to reduce inflammation and secondary damage during neuronal disease or injury. HDAC inhibition is a promising therapeutic method for the treatment of a series of disorders of the central nervous system (Langley B et al., 2005, Current Drug Targets - CNS & Neurological Disorders, 4: 41-50).
[00010] Histone deacetylase is known to play an essential role in the transcriptional mechanism to regulate gene expression, induce histone hyperacetylation and to affect gene expression. Therefore, it is useful as a therapeutic or prophylactic agent for diseases caused by abnormal gene expression such as inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukemia (APL), organ transplant rejections, autoimmune diseases, protozoal infections, tumors, etc.
[00011] Thus, there remains a need for the development of new inhibitors of histone deacetylases and histone deacetylases from tubulin. In particular, inhibitors that are more potent and / or more specific to their particular target than the known HDAC and TDAC inhibitors. HDAC inhibitors specific to a certain class or family member of HDAC would be particularly useful both in the treatment of proliferative diseases and protein deposition disorders and in the study of HDACs, particularly HDAC6. Inhibitors that are specific for HDAC versus TDAC and vice versa are also useful in treating disease and probing biological trails. The present invention provides new compounds, pharmaceutical compositions thereof, and methods of employing these compounds to treat HDAC6-related disorders including cancers, inflammatory, autoimmune, neurological and neurodegenerative disorders. SUMMARY OF THE INVENTION
[00012] In one aspect, the invention provides a compound of formula I:
or a prodrug, ester or pharmaceutically acceptable salt thereof, where,
[00013] Z is N or CR *, where R * is optionally substituted alkyl, optionally substituted acyl, optionally substituted aryl or optionally substituted heteroaryl;
[00014] ring A is an optionally substituted aryl or an optionally substituted heteroaryl;
[00015] ring B is an optionally substituted aryl or an optionally substituted heteroaryl;
[00016] R1 is (i) H, alkyl, haloalkyl, alkenyl, aryl, arylalkyl, heteroaryl, heterocyclic, carbocyclic, C (O) -R2, C (O) O-R2, or S (O) P, each of which can be optionally replaced; or (ii) when Z is CR *, R1 can be optionally substituted branched alkyl, OR3, OR N (R3) (R3), -CH2CH2OH, OCH2CH2OH, SH, or thio alkoxy;
[00017] or ring B and Ri can together with the atom to which each is attached, form an optionally substituted heterocyclic, or an optionally substituted heteroaryl;
[00018] or R * and Ri together with the atom to which each is attached, can form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl or optionally substituted heteroaryl ring;
[00019] R is H or an optionally substituted alkyl; or R and 0 ring A can be linked to form a fused bicyclic ring that can be optionally substituted;
[00020] each R2 is independently alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[00021] each R3 is independently alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[00022] n is 4, 5, 6, 7 or 8; and
[00023] foot 0.1, or 2.
[00024] In another aspect, the invention provides a pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable prodrug, salt or ester thereof, together with a pharmaceutically acceptable carrier.
[00025] In one aspect, the invention provides a method of inhibiting a histone deacetylase (HDAC) in an individual, comprising administering a compound of formula I
or a prodrug, ester or pharmaceutically acceptable salt thereof, where,
[00026] Z is N or CR *, where R * is optionally substituted alkyl, optionally substituted acyl, optionally substituted aryl or optionally substituted heteroaryl;
[00027] ring A is an optionally substituted aryl or an optionally substituted heteroaryl;
[00028] ring B is an optionally substituted aryl or an optionally substituted heteroaryl;
[00029] Ri is (i) H, alkyl, haloalkyl, alkenyl, aryl, arylalkyl, heteroaryl, heterocyclic, carbocyclic, C (O) -R2, C (O) O-R2, or S (O) P, each of which can be optionally replaced; or (ii) when Z is CR *, R1 can be optionally substituted branched alkyl, OR3, OR N (R3) (R3), -CH2CH2OH, OCH2CH2OH, SH, or thio alkoxy;
[00030] or the ring B and Ri can together with the atom to which each is attached, form an optionally substituted heterocyclic, or an optionally substituted heteroaryl;
[00031] or R * and Ri together with the atom to which each is attached, can form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl or optionally substituted heteroaryl ring;
[00032] R is H or an optionally substituted alkyl; or R and ring A can be linked to form a fused bicyclic ring that can be optionally substituted;
[00033] each R2 is independently alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[00034] each R3 is independently alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[00035] n is 4, 5, 6, 7 or 8; and
[00036] footO, 1, or2.
[00037] In another aspect, the invention provides a method of treating an HDAC-6-mediated disease in an individual comprising administering to the individual a compound of formula I
or a prodrug, ester or pharmaceutically acceptable salt thereof, where,
[00038] Z is N or CR *, where R * is optionally substituted alkyl, optionally substituted acyl, optionally substituted aryl or optionally substituted heteroaryl;
[00039] Ring A is an optionally substituted aryl or an optionally substituted heteroaryl;
[00040] Ring B is an optionally substituted aryl or an optionally substituted heteroaryl;
[00041] Ri is (i) H, alkyl, haloalkyl, alkenyl, aryl, arylalkyl, heteroaryl, heterocyclic, carbocyclic, C (O) -R2, C (O) O-R2, or S (O) P, each of which can be optionally replaced; or (ii) when Z is CR *, R1 can be optionally substituted branched alkyl, OR3, or N (R3) (R3), -CH2CH2OH, OCH2CH2OH, SH, or thio alkoxy;
[00042] or the ring B and Ri can together with the atom to which each is attached, form an optionally substituted heterocyclic, or an optionally substituted heteroaryl;
[00043] or R * and Ri together with the atom to which each is attached, can form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl or optionally substituted heteroaryl ring;
[00044] R is H or an optionally substituted alkyl; or R and 0 ring A can be linked to form a fused bicyclic ring that can be optionally substituted;
[00045] each R2 is independently alkyl, cycloalkyl, hetero-cycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[00046] each R3 is independently alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[00047] n is 4, 5, 6, 7 or 8; and
[00048] footO, 1, or2.
[00049] In other respects, the invention provides a method of treating an individual suffering from or susceptible to multiple myeloma comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I,
or a prodrug, ester or pharmaceutically acceptable salt thereof, where,
[00050] Z is N or CR *, where R * is optionally substituted alkyl, optionally substituted acyl, optionally substituted aryl or optionally substituted heteroaryl;
[00051] ring A is an optionally substituted aryl or an optionally substituted heteroaryl;
[00052] ring B is an optionally substituted aryl or an optionally substituted heteroaryl;
[00053] Ri is (i) H, alkyl, haloalkyl, alkenyl, aryl, arylalkyl, heteroaryl, heterocyclic, carbocyclic, C (O) -R2, C (O) O-R2, or S (O) P, each of which can be optionally replaced; or (ii) when Z is CR *, R1 can be optionally substituted branched alkyl, OR3, OR N (R3) (R3), -CH2CH2OH, OCH2CH2OH, SH, or thio alkoxy;
[00054] or the ring B and Ri can together with the atom to which each is attached, form an optionally substituted heterocyclic, or an optionally substituted heteroaryl;
[00055] or R * and Ri together with the atom to which each is attached, can form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl or optionally substituted heteroaryl ring;
[00056] R is H or an optionally substituted alkyl; or R and 0 ring A can be linked to form a fused bicyclic ring that can be optionally substituted;
[00057] each R2 is independently alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[00058] each R3 is independently alkyl, cycloalkyl, hetero-cycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[00059] n is 4, 5, 6, 7 or 8; and
[00060] footO, 1, or2;
[00061] to thereby treat the individual suffering from or susceptible to multiple myeloma.
[00062] In another aspect, the invention provides a kit comprising a compound capable of inhibiting HDAC activity selected from one or more compounds of formula I
or a prodrug, ester or pharmaceutically acceptable salt thereof, where,
[00063] Z is N or CR *, where R * is optionally substituted alkyl, optionally substituted acyl, optionally substituted aryl or optionally substituted heteroaryl;
[00064] ring A is an optionally substituted aryl or an optionally substituted heteroaryl;
[00065] ring B is an optionally substituted aryl or an optionally substituted heteroaryl;
[00066] Ri is (i) H, alkyl, haloalkyl, alkenyl, aryl, arylalkyl, heteroaryl, heterocyclic, carbocyclic, C (O) -R2, C (O) O-R2, or S (O) P, each of which can be optionally replaced; or (ii) when Z is CR *, R1 can be optionally substituted branched alkyl, OR3, OR N (R3) (R3), -CH2CH2OH, OCH2CH2OH, SH, or thio alkoxy;
[00067] or the ring B and Ri can together with the atom to which each is attached, form an optionally substituted heterocyclic, or an optionally substituted heteroaryl;
[00068] or R * and Ri together with the atom to which each is attached, can form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl or optionally substituted heteroaryl ring;
[00069] R is H or an optionally substituted alkyl; or R and 0 ring A can be linked to form a fused bicyclic ring that can be optionally substituted;
[00070] each R2 is independently alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[00071] each R3 is independently alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[00072] n is 4, 5, 6, 7 or 8; and
[00073] foot 0.1, or 2;
[00074] and instructions for use in the treatment of multiple myeloma. DETAILED DESCRIPTION OF THE INVENTION Definitions
[00075] Listed below are definitions of various terms used to describe this invention. These definitions apply to the terms as they are used in all of this specification and claims, unless otherwise limited in the specific examples, individually or as part of a larger group.
[00076] The term "alkyl," as used herein, refers to portions of saturated straight or branched chain hydrocarbon containing, in certain embodiments, between one and six, or one and eight carbon atoms, respectively. Examples of Ci-Ce alkyl moieties include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl, n-hexyl moieties; and examples of C1-6 alkyl moieties include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl, n-hexyl, heptyl, and octyl moieties.
[00077] The term "alkenyl," as used here, denotes a monovalent group derived from a hydrocarbon moiety containing, in certain embodiments, two to six, or two to eight carbon atoms having at least one carbon-carbon double bond. . The double bond may or may not be the point of attachment to another group. Alkenyl groups include, but are not limited to, for example, ethylene, propenyl, butenyl, 1-methyl-2-buten-1-yl, heptenyl, octenyl and the like).
[00078] The term "alkynyl", as used here, denotes a monovalent group derived from a hydrocarbon moiety containing, in certain embodiments, two to six, or two to eight carbon atoms having at least one carbon-carbon triple bond . The alkynyl group may or may not be the point of attachment to another group. Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, heptinyl, octinyl and the like (s).
[00079] The term "alkoxy" refers to an -O-alkyl moiety.
[00080] The term "aryl," as used herein, refers to a mono- or polycyclic carbocyclic ring system having one or more aromatic rings, fused or unfused, including, but not limited to, phenyl, naphthyl, tetra- hydronaftyl, indanyl, idenyl and similar (s).
[00081] The term "aralkyl," or "arylalkyl," as used here, refers to an alkyl residue attached to an aryl ring. Examples include, but are not limited to, benzyl, phenethyl and the like (s).
[00082] The term “carbocyclic,” as used here, denotes a monovalent group derived from a saturated, partially unsaturated, or completely unsaturated, monocyclic or polycyclic carbocyclic ring compound. Examples of carbocyclic groups include groups found in the cycloalkyl definition and aryl definition.
[00083] The term "cycloalkyl," as used here, denotes a monovalent group derived from a saturated or partially unsaturated monocyclic or polycyclic carbocyclic ring compound. Examples of Cs-Ce-cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl and cyclooctyl; and examples of C3-C12-cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [2.2.1] heptyl, and octyl bicyclo [2.2.2]. Also contemplated are monovalent groups derived from a monocyclic or polycyclic carbocyclic ring compound having at least one double bond by removing a single hydrogen atom. Examples of such groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloeptenyl, cyclooctenyl, and the like (s).
[00084] The term "heteroaryl," as used herein, refers to a ring system or mono or polycyclic portions (e.g., bi, or tri-cyclic or more) fused or unfused having at least one aromatic ring, having five to ten ring atoms of which one ring atom is selected from S, O and N; zero, one or two ring atoms are additional hetero atoms independently selected from S, O and N; and the remaining ring atoms are carbon. Heteroaryl includes, but is not limited to, pyridinyl, pyrazinyl, pyrimidinyl, pyrrole, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinoline, benzoyl, benzyl similar (s).
[00085] The term "heteroaralkyl," as used here, refers to an alkyl residue attached to a heteroaryl ring. Examples include, but are not limited to, pyridinylmethyl, pyrimidinylethyl and the like).
[00086] The term "heterocycloalkyl," as used herein, refers to a 3, 4, 5, 6 or 7-membered non-aromatic ring or a fused bi or tricyclic group of the non-fused system, where (i) each ring contains between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, (ii) each 5-membered ring has 0 to 1 double bonds and each 6-membered ring has 0 to 2 double bonds, (iii) hetero atoms of nitrogen and sulfur can be optionally oxidized, (iv) the nitrogen heteroatom can optionally be quaternized and (iv) any of the above rings can be fused to a benzene ring. Representative heterocycloalkyl groups include, but are not limited to, [1,3] dioxolane, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, eothia hydrofuril.
[00087] The term "alkylamino" refers to a group having the structure
[00088] -NH (C1 -C12 alkyl) where C1-C12 alkyl is as previously defined.
[00089] The term "acyl" includes residues derived from acids, including but not limited to carboxylic acids, carbonic acids, carbonic acids, sulfonic acids, and phosphorous acids. Examples include aliphatic carbonyls, aromatic carbonyls, aliphatic sulfonyls, aromatic sulfinyls, aliphatic sulfinyls, aromatic phosphates and aliphatic phosphates. Examples of aliphatic carbonyls include, but are not limited to, acetyl, propionyl, 2-fluoroacetyl, butyryl, 2-hydroxy acetyl, and the like (s).
[00090] According to the invention, any of the aryls, substituted aryls, heteroaryls and substituted heteroaryls described herein, can be any aromatic group. Aromatic groups can be substituted or unsubstituted.
[00091] The terms "hal," "halo" and "halogen," as used here, refer to an atom selected from fluorine, chlorine, bromine and iodine.
[00092] The term "oxo" as used here, refers to an oxygen that is attached to a carbon, preferably by a double bond (for example, carbonyl).
[00093] As described herein, the compounds of the invention can optionally be substituted with one or more substituents, such as are generally illustrated above, or as exemplified by particular classes, subclasses, and species of the invention. It will be appreciated that the phrase "optionally substituted" is used interchangeably with the phrase "substituted or not substituted." In general, the term "substituted", whether preceded by the term "optionally" or not, refers to the replacement of hydrogen radicals in a structure provided with the radical of a specified substituent. Unless otherwise indicated, an optionally substituted group may have one substituent at each replaceable position in the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent can be the same or different in each position. The terms "optionally substituted", "optionally substituted alkyl," "optionally substituted alkenyl," "optionally substituted alkynyl", "optionally substituted cycloalkyl," "optionally substituted cycloalkenyl," "optionally substituted aryl", "optionally substituted heteroaryl," " optionally substituted aralkyl ”,“ optionally substituted heteroaralkyl, ”“ optionally substituted heterocycloalkyl, ”and any other optionally substituted group as employed herein, refer to groups that are substituted or not substituted by the independent substitution of one, two, or three or more of the hydrogen atoms in it with substituents including, but not limited to:
[00094] alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, arylalkyl, heteroarylalkyl,
[00095] -F, -Cl, -Br, -I,
[00096] -OH, protected hydroxy, oxygen, oxo,
[00097] -NO2, -CN,
[00098] -NH2, protected amino, -NH -Ci-C12 -alkyl, -NH -aryl, -dial-quilamino, -
[00099] -O-Ci-Ci2-alkyl, -O-aryl,
[000100] -C (O) -, -C (O) O-, -C (O) NH-, -OC (O) -, -OC (O) O-, -OC (O) NH-, - NHC (O) -, -NHC (O) O-,
[000101] -C (O) - C1-C2-alkyl, -C (O) -C3-C2-cycloalkyl, -C (O) -aryl, -C (O) -heteroaryl, -C (O) -heterocycloalkyl ,
[000102] -C (O) O-C1-C2-alkyl, -C (O) O-C3-C2-cycloalkyl, -C (O) O-aryl, -C (O) O-heteroaryl, -C ( O) O-heterocycloalkyl,
[000103] -CONH2, -CONH- C1 -Ci2-alkyl, - -CONH-aryl,
[000104] -OCO2- Ci-Ci2-alkyl, -OCO2-aryl, -OCONH2, -OCONH- Ci-Ci2-alkyl, -OCONH- aryl,
[000105] -NHC (O) - C1-C2-alkyl, -NHC (O) -aryl, -NHCO2- C1-C12-alkyl, -NHCO2-aryl,
[000106] -S (O) -Ci-Ci2-alkyl, -S (O) -aryl, -SO2NH- Ci-Ci2-alkyl, -SO2NH-aryl,
[000107] -NHSO2-C1-C2-alkyl, -NHSO2-aryl,
[000108] -SH, -S-C1 -C12 -alkyl, or -S-aryl.
[000109] In certain embodiments, the optionally substituted groups include the following: C1-C2-alkyl, C2-C2-alkenyl, C2-C12-alkynyl, C3-C2-cycloalkyl, C3-C2-aryl, C3-C2-heterocycloalkyl , C3-Ci2-heteroaryl, C4-Ci2-arylalkyl, or C2-Ci2-heteroarylalkyl.
[000110] It is understood that aryls, heteroaryls, alkyls, and the like) can also be replaced.
[000111] As used herein, the term "metal chelator" refers to any molecule or portion that is capable of forming a complex (ie, "chelates") with a metal ion www. In certain exemplary embodiments, a chelator Metal refers to any molecule or portion that "binds" to a metal ion, in solution, making it unavailable for use in chemical / enzymatic reactions. In certain embodiments, the solution comprises aqueous media under physiological conditions. Examples of metal ions include, but are not limited to, Ca2 +, Fe3 +, Zn2 +, Na +, etc. in certain modalities, the metal chipper binds to Zn2 +. In certain embodiments, the portion molecules that precipitate metal ions are not considered to be metal breakers.
[000112] As used herein, the term "small molecule" refers to a non-peptide, non-oligomeric organic compound synthesized in the laboratory or found in nature. Small molecules, as used here, may refer to compounds that are "natural product type", however, the term "small molecule" is not limited to "natural product type" compounds. Preferably, a small molecule is typically characterized by it contains several carbon-carbon bonds, and has a molecular weight of less than 1500, although this characterization is not intended to be limiting for the purposes of the present invention. Examples of "small molecules" that occur in nature include, however are not limited to, taxol, dinemicin, and rapamycin In certain other preferred embodiments, small molecules like natural product are used.
[000113] The term "individual" as used here refers to a mammal. An individual, therefore, refers to, for example, dogs, cats, horses, cows, pigs, guinea pigs, and the like (s). Preferably, the individual is a human being. When the individual is a human being, the individual can be referred to here as a patient.
[000114] "Treat", "treating" and "treatment" refer to a method of relieving or reducing a disease and / or its accompanying symptoms.
[000115] As used herein, the term "pharmaceutically acceptable salt" refers to those salts of the compounds formed by the process of the present invention which are, within the scope of safe medical diagnosis, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like (s), and are commensurable with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, and other (s) describe the pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). Salts can be prepared in situ during the final purification and isolation of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid. Examples of pharmaceutically acceptable include, but are not limited to, non-toxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or using other methods employed in the art such as ion exchange. Other pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphor sulfate, citrate, cyclopentanopropionate, diglucone, dodecyl sulfate, ethanossosate glucoeptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxyethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfate, nitrate naphthalene oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like (es). Representative alkaline earth metal or alkali salts include sodium, lithium, potassium, calcium, magnesium, and the like (s). Other pharmaceutically acceptable salts include, where appropriate, non-toxic ammonium, quaternary ammonium and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having 1 to 6 carbon atoms, sulfonate and aryl sulfonate.
[000116] As used herein, the term "pharmaceutically acceptable ester" refers to the esters of compounds formed by the process of the present invention which hydrolyzes in vivo and includes those that break easily in the human body to leave the parent compound or a salt this. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenic, cycloalkanoic and alkanedioic acids, wherein each alkyl or alkenyl moiety advantageously does not have more than 6 carbon atoms. Examples of particular esters include, but are not limited to, formate, acetate, propionate, butyrate, acrylate and ethyl succinate.
[000117] The term "pharmaceutically acceptable prodrugs" as used herein refers to those prodrugs of the compounds formed by the process of the present invention which are, within the scope of safe medical diagnosis, suitable for use in contact with human tissues and inferior animals with undue toxicity, irritation, allergic response, and similar (s), commensurable with a benefit / risk ratio, and effective for their intended use, as well as the hybrid forms, where possible, of the compounds of the present invention. "Prodrug" as used herein means a compound that is convertible in vivo by metabolic means (for example, by hydrolysis) to provide any compound outlined by the formulas of the present invention. Various forms of prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder, and other (ed.), Methods in Enzymology, vol. 4, Academic Press (1985); Krogsgaard-Larsen, and other (s), (ed). "Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191 (1991); Bundgaard, and other (s), Journal of Drug Deliver Reviews, 8: 1-38 (1992); Bundgaard , J. of Pharmaceutical Sciences, 77: 285 et seq. (1988); Higuchi and Stella (eds.) Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975); and Bernard Testa & Joachim Mayer, “Hydrolysis In Drug and Prodrug Metabolism: Chemistry, Biochemistry and Enzymology, ”John Wiley and Sons, Ltd. (2002).
[000118] This invention also encompasses pharmaceutical compositions containing, and methods of treating disorders by administering, pharmaceutically acceptable prodrugs of the compounds of the invention. For example, compounds of the invention having free amino, starch, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds in which an amino acid residue, or a polypeptide chain of two or more (for example, two, three or four) amino acid residues is covalently linked via an amide or ester bond to an amino free, hydroxy or carboxylic acid group of the compounds of the invention. Amino acid residues include, but are not limited to, 20 naturally occurring amino acids commonly referred to as three letter symbols and also include 4-hydroxyproline, hydroxysine, demosine, isodemosine, 3-methylhistidine, norvaline, beta-alanine, gamma-aminobutyric acid , citrulline, homocysteine, homoserine, ornithine and methionine sulfone. Additional types of prodrugs are also covered. For example, free carboxyl groups can be derived as amides or alkyl esters. Free hydroxy groups can be derived using groups including, but not limited to, hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxy carbonyls, as outlined in Advanced Drug Delivery Reviews, 1996, 19, 1 15. The group carbamate prodrugs hydroxy and amino are also included, as are the carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups. Derivation of hydroxy groups such as (acyloxy) methyl and (acyloxy) ethyl ethers in which the acyl group can be an alkyl ester, optionally substituted with groups including but not limited to, carboxylic acid, amine and ether functionalities, or where the acyl group is an amino acid ester as described above, are also covered. Prodrugs of this type are described in J. Med. Chem. 1996, 39, 10. Free amines can also be derived as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including, but not limited to, carboxylic acid, amine and ether functionalities.
[000119] The combinations of the substituents and variables provided for by this invention are only those that result in the formation of stable compounds. The term "stable", as used herein, refers to compounds that have sufficient stability to permit manufacture and that maintain the integrity of the compound for a sufficient period of time to be useful for the purposes detailed here (for example, therapeutic administration or prophylactic to an individual).
[000120] The terms "isolated," "purified," or "biologically pure" refer to material that is substantially or essentially free of components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. In particular, in the embodiments the compound is at least 85% pure, more preferably at least 90% pure, more preferably at least 95% pure, and most preferably at least 99% pure. Compounds of the Invention
[000121] In one aspect, the invention provides a compound of formula I:
or a prodrug, ester or pharmaceutically acceptable salt thereof, where,
[000122] Z is N or CR *, where R * is optionally substituted alkyl, optionally substituted acyl, optionally substituted aryl or optionally substituted heteroaryl;
[000123] ring A is an optionally substituted aryl or an optionally substituted heteroaryl;
[000124] ring B is an optionally substituted aryl or an optionally substituted heteroaryl;
[000125] Ri is (i) H, alkyl, haloalkyl, alkenyl, aryl, arylalkyl, heteroaryl, heterocyclic, carbocyclic, C (O) -R2, C (O) O-R2, or S (O) P, each of which can be optionally replaced; or (ii) when Z is CR *, R1 can be optionally substituted branched alkyl, OR3, OR N (R3) (R3), -CH2CH2OH, OCH2CH2OH, SH, or thio alkoxy;
[000126] or the ring B and Ri can together with the atom to which each is attached, form an optionally substituted heterocyclic, or an optionally substituted heteroaryl;
[000127] or R * and Ri together with the atom to which each is attached, can form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl or optionally substituted heteroaryl ring;
[000128] R is H or an optionally substituted alkyl; or R and 0 ring A can be linked to form a fused bicyclic ring that can be optionally substituted;
[000129] each R2 is independently alkyl, cycloalkyl, hetero-cycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[000130] each R3 is independently alkyl, cycloalkyl, hetero-cycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[000131] n is 4, 5, 6, 7 or 8; and
[000132] foot 0.1, or 2.
[000133] In one embodiment, ring A is phenyl, naphthyl, anthracenyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, imidazolyl, oxazolyl, furyl, thienyl, thiazolyl, triazolyl, isoxazolyl, quinolinyl, pyrrolyl, 5, pyrazolyl, 5 7,8-tetrahydroisoquinoline; each of which can be optionally replaced.
[000134] In another embodiment, ring B is phenyl, naphthyl, anthracenyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, imidazolyl, oxazolyl, furyl, thienyl, thiazolyl, triazolyl, isoxazolyl, quinolinyl, pyrrolyl, 5, pyrazolyl, 5 7,8-tetrahydroisoquinoline; each of which can be optionally replaced.
[000135] In certain embodiments, Ri is H, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl, or Ri is OH or alkoxy.
[000136] In another embodiment, Ri is H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, phenyl, naphthyl, pyridinyl, OH, OCH3, OCH2CH3, O- Pr, O-iPr, O-Bu, O-sBu, or O-tBu; each of which can be optionally replaced.
[000137] In various embodiments, Ri is OH, alkoxy, NH2, NH (alkyl), N (alkyl) (alkyl), NH-aryl, NH-heteroaryl, N (aryl) (aryl), N (aryl) (heteroaryl ), or N (heteroaryl) (heteroaryl).
[000138] In other embodiments, the carbonyl and the Z group attached to ring A are arranged towards each other.
[000139] In other embodiments, the carbonyl and the Z group attached to ring A are arranged meta-together.
[000140] In another embodiment, the carbonyl and the Z group attached to ring A are arranged ortho to each other.
[000141] In one embodiment, the invention provides a compound of formula II:
or a prodrug, ester or pharmaceutically acceptable salt thereof, where,
[000142] each of Xi, X2, X3, or X4 is independently N, CR ', O, S, NCR', CR'CR ', OCR', SCR ', or absent, or Xi or X4 can be linked with R to form a bicyclic ring; where up to three of Xi, X2, X3, or X4 can be N;
[000143] Ring B is an optionally substituted aryl or an optionally substituted heteroaryl;
[000144] Ri is H, alkyl, haloalkyl, alkenyl, aryl, arylalkyl, heteroaryl, heterocyclic, carbocyclic, C (O) -R2, or C (O) O-R2, each of which can be optionally substituted;
[000145] R is H or an optionally substituted alkyl; or R and Xi or X4 can be linked to form a fused bicyclic ring that can be optionally substituted;
[000146] each R 'is independently H, optionally substituted alkyl, halo, OH, NH2, NHR ", haloalkyl, CN, N3, NO2;
[000147] R "is H or alkyl; and
[000148] R2 is alkyl, cycloalkyl, heterocycloalkyl, aryl, or hetero aryl, each of which is optionally substituted.
[000149] In certain embodiments, Xi, X2, X3, and X4 are all CR. . x / can M A Xi θ X4 are CR ■
[000150] In other modalities, X2 θ X3, are ixi and
[000151] In another modality, X2 and X3, are CR and Xi θ X4 s, Yn p N ‘X3 is S, N or O; Xi is
[000152] In still other modalities, X2, θ N, ™ CR 'and X4 is absent.
[000153] In one embodiment, ring B is phenyl, pyridinyl, pyrimidinyl, or pyrazinyl; each of which can be optionally replaced.
[000154] In another embodiment, ring B is replaced by alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, haloalkyl, hal, OH, NH2, NHR ”, CN, N3, or NO2.
[000155] In certain embodiments, Ri is H, alkyl, aryl, arylalkyl, or heteroaryl, each of which can be optionally substituted.
[000156] In another embodiment, the invention provides a compound of formula III:
or a prodrug, ester or pharmaceutically acceptable salt thereof, where,
[000157] ring B is an optionally substituted aryl or an optionally substituted heteroaryl;
[000158] Ri is H, alkyl, haloalkyl, alkenyl, aryl, arylalkyl, heteroaryl, heterocyclic, carbocyclic, C (O) -R2, or C (O) O-R2, each of which can be optionally substituted;
[000159] R2 is optionally substituted Heteroaryl, and
[000160] R is H or an optionally substituted alkyl; or R and the phenyl ring can be linked to form a fused bicyclic ring [6.5] which can be optionally substituted.
[000161] In one embodiment, ring B is phenyl, pyridinyl, pyrimidinyl, or pyrazinyl; each of which can be optionally replaced.
[000162] In another embodiment, ring B is replaced by alkyl, aryl, aralkyl, haloalkyl, hal, OH, NH2, CN, or NO2.
[000163] In other embodiments, Ri is H, alkyl, aryl, arylalkyl, heteroaryl, C (O) -R2, or C (O) O-R2, each of which can be optionally substituted.
[000164] In several embodiments, R2 is optionally substituted pyridinyl.
[000165] In another embodiment, the invention provides a compound of formula IV:
or a prodrug, ester or pharmaceutically acceptable salt thereof, where,
[000166] Ring B is an optionally substituted aryl or an optionally substituted heteroaryl;
[000167] Ri is H, alkyl, haloalkyl, alkenyl, aryl, arylalkyl, heteroaryl, heterocyclic, or carbocyclic, each of which can be optionally substituted;
[000168] or the ring B and Ri can together with the atom to which each is attached, form an optionally substituted heterocyclic, or an optionally substituted heteroaryl, and
[000169] R is H or an optionally substituted alkyl; or R and the 1,3-pyrimidinyl ring can be linked to form a fused bicyclic ring that can be optionally substituted.
[000170] In certain embodiments, ring B is phenyl, pyridinyl, pyrimidinyl, or pyrazinyl; each of which can be optionally replaced.
[000171] In another embodiment, ring B is replaced by alkyl, aryl, aralkyl, haloalkyl, halo, OH, NH2, CN, or NO2.
[000172] In other embodiments, Ri is H, alkyl, aryl, arylalkyl, or heteroaryl, each of which can be optionally substituted.
[000173] In another embodiment, Ri is replaced by OH or halo.
[000174] In certain embodiments, the ring formed by ring B and Ri is piperidine, pyrrolidine, tetrahydroquinoline, morpholine, piperazine, tetrahydro triazole pyrazine, or diazepane, each of which is optionally substituted.
[000175] In another embodiment, the invention provides a compound of formula V:
or a prodrug, ester or pharmaceutically acceptable salt thereof, where,
[000176] each of Xi, X2, or X3 is independently N or CR ';
[000177] Ring B is an optionally substituted aryl or an optionally substituted heteroaryl;
[000178] Ri is H, alkyl, haloalkyl, alkenyl, aryl, arylalkyl, heteroaryl, heterocyclic, or carbocyclic, each of which can be optionally substituted;
[000179] each RAe RB is independently H, NH (Rc), N (Rc) (Rc), N (Rc) CO (Rc), CO2H, C (O) Rc, C (O) ORc, C (O) NH2 , C (O) NH (Rc), C (O) N (Rc) (Rc), SO2RC, SORc, SRc, alkyl, aryl, arylalkyl, alkoxy, heteroaryl, heterocyclic, and carbocyclic, each of which can also be substituted; or RAθ RB together with 0 carbon to which they are attached form a carbonyl;
[000180] each Rc is independently H, alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, or heterocyclic, each of which can also be substituted;
[000181] R 'is H, optionally substituted alkyl, halo, OH, NH2, NHR ”, haloalkyl, CN, N3, NO2;
[000182] R "is H or alkyl; and
[000183] method 1 or 2.
[000184] In a related embodiment, the invention provides a compound of formula Va:
or a prodrug, ester or pharmaceutically acceptable salt thereof, where,
[000185] each of Xi, X2, or X3 is independently N or CR ';
[000186] Ring B is an optionally substituted aryl or an optionally substituted heteroaryl;
[000187] Ri is H, alkyl, haloalkyl, alkenyl, aryl, arylalkyl, heteroaryl, heterocyclic, or carbocyclic, each of which can be optionally substituted;
[000188] each RAe RBθ independently H, NH (Rc), N (Rc) (Rc), N (Rc) CO (Rc), CO2H, C (O) Rc, C (O) ORc, C (O) NH2 , C (O) NH (Rc), C (O) N (Rc) (Rc), SO2RC, SORc, SRc, alkyl, aryl, arylalkyl, alkoxy, heteroaryl, heterocyclic, and carbocyclic, each of which can also be replaced; or RA and RB together with the carbon to which they are attached form a carbonyl;
[000189] each Rc is independently H, alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, or heterocyclic, each of which can also be substituted;
[000190] R 'is H, optionally substituted alkyl, halo, OH, NH2, NHR ”, haloalkyl, CN, N3, NO2;
[000191] R "is H or alkyl; and
[000192] method 1 or 2.
[000193] In one embodiment, Xi, X2, and X3, are all independently CR '.
[000194] In another embodiment, ring B is phenyl, pyridinyl, pyrimidinyl, or pyrazinyl; each of which can be optionally replaced.
[000195] In another embodiment, ring B is replaced by alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, haloalkyl, halo, OH, NH2, NHR ”, CN, N3I OR NO2.
[000196] In certain embodiments, Ri is H, alkyl, aryl, arylalkyl, or heteroaryl, each of which can be optionally substituted.
[000197] In another embodiment, the invention provides a compound of formula VI:
or a prodrug, ester or pharmaceutically acceptable salt thereof, where,
[000198] ring B is an optionally substituted aryl or an optionally substituted heteroaryl;
[000199] R * is an optionally substituted alkyl, an optionally substituted aryl or an optionally substituted heteroaryl;
[000200] Ri is H, alkyl, aryl, arylalkyl, heteroaryl, heterocyclic, carbocyclic, OH, alkoxy, NH2, NH (alkyl), or N (alkyl) (alkyl);
[000201] or R * and Ri together with the atom to which each is attached, can form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl or optionally substituted heteroaryl ring; and
[000202] R is H or an optionally substituted alkyl.
[000203] In one embodiment, ring B is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or thiazole; each of which can be optionally replaced.
[000204] In another embodiment, R * is methyl, trifluoromethyl, phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or thiazole; each of which can be optionally replaced.
[000205] In certain embodiments, Ri is OH, methoxy, or ethoxy.
[000206] In various embodiments, rings B and R * are each independently substituted with one or more of alkyl, halogen, or C (O) NRXRY, where Rx is H or alkyl, and RY is H or alkyl .
[000207] In other modalities, rings B and R * are each independently replaced with one or more of methyl, F, or C (O) N (Me) 2.
[000208] In another aspect, the invention provides a pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable prodrug, salt or ester thereof, together with a pharmaceutically acceptable carrier.
[000209] Representative compounds of the invention include, but are not limited to, the following compounds in Table 1 below. Table 1

















[000210] In preferred embodiments, a compound useful in the invention has one or more of the following properties: the compound is capable of inhibiting at least one histone deacetylase; the compound is capable of inhibiting HDAC6; the compound is a selective HDAC6 inhibitor; the compound binds to the HDAC6 poly-ubiquitin binding domain; the compound is capable of inducing apoptosis in cancer cells (especially multiple myeloma cells, non-Hodgkin's lymphoma (NML) cells, breast cancer cells, acute myelogenous leukemia (AML) cells); and / or the compound is able to inhibit the formation of agressoma.
[000211] In certain preferred embodiments, a compound of the invention comprises a metal binding moiety, preferably a zinc binding moiety such as a hydroxamate. As mentioned above, certain hydroxamates are potent inhibitors of HDAC6 activity; without wishing to be bound by theory, it is believed that the potency of these hydroxamates is due, at least in part, to the ability of the compounds to bind to zinc. In preferred embodiments, a compound of the invention includes at least a portion or region that can confer selectivity to a biological target involved in the agressoma trail, for example, a biological target having tubulin deacetylase (TDAC) or HDAC activity, for example, HDAC6 . Thus, in certain preferred embodiments, a compound of the invention includes a zinc binding portion spaced from other portions of the molecule that are responsible for binding to the biological target.
[000212] The invention also provides a pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable prodrug, salt or ester thereof, together with a pharmaceutically acceptable carrier.
[000213] Another object of the present invention is the use of a compound as described here (for example, of any formulas here) in the manufacture of a medicament for use in the treatment of a disorder or disease here. Another object of the present invention is the use of a compound as described here (for example, of any formulas here) for use in the treatment of a disorder or disease here.
[000214] In another aspect, the invention provides a method of synthesizing a compound of formula I. The synthesis of the compounds of the invention can be found in the Examples below.
[000215] Another modality is a method of preparing a compound of any of the formulas here using any, or combination of, reactions outlined here. The method may include the use of one or more intermediates or chemical reagents outlined here.
[000216] Another aspect is an isotopically labeled compound of any of the formulas outlined here. Such compounds have one or more isotope atoms which may or may not be radioactive (for example, 3H, 2H, 14C, 13C, 35S, 32P, 125l, and 131l) introduced into the compound. Such compounds are useful for diagnostics and studies of drug metabolism, as well as therapeutic applications.
[000217] A compound of the invention can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable organic or inorganic acid. Alternatively, a pharmaceutically acceptable base addition salt of a compound of the invention can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable organic or inorganic base.
[000218] Alternatively, the salt forms of the compounds of the invention can be prepared using salts of the starting materials or intermediates.
[000219] The free acid or free base forms of the compounds of the invention can be prepared in the corresponding form of base addition salt or acid addition salt, respectively. For example, a compound of the invention in an acid addition salt form can be converted to the corresponding free base by treating it with a suitable base (for example, ammonium hydroxide solution, sodium hydroxide, and the like (s)) . A compound of the invention in a base addition salt form can be converted to the corresponding free acid by treating it with a suitable acid (for example, hydrochloric acid, etc.).
[000220] Prodrug derivatives of the compounds of the invention can be prepared by methods known to those skilled in the art (for example, for further details see Saulnier et al. (1994), Bioorganic and Medicinal Chemistry Letters, Vol 4, p. 1985). For example, suitable prodrugs can be prepared by reacting a non-derivative compound of the invention with a suitable carbamylating agent (for example, 1,1-acyloxyalkylcarbanochlorhydrate, para-nitrophenyl carbonate, or the like)).
[000221] The protected derivatives of the compounds of the invention can be prepared by means known to those skilled in the art. A detailed description of the techniques applicable to the creation of protection groups and their removal can be found in T. W. Greene, "Protecting Groups in Organic Chemistry", 3rd edition, John Wiley and Sons, Inc., 1999, and subsequent editions thereof.
[000222] The compounds of the present invention can be conveniently prepared, or formed during the process of the invention, as solvates (for example, hydrates). The hydrates of the compounds of the present invention can be conveniently prepared by re-crystallizing an aqueous / organic solvent mixture, using organic solvents such as dioxane, tetrahydrofuran or methanol.
[000223] Acids and bases useful in the included methods are known in the art. Acid catalysts are any acidic chemical, which can be inorganic (for example, hydrochloric, sulfuric, nitric, aluminum trichloride) or organic (for example, camphorsulfonic acid, p-toluenesulfonic acid, acetic acid, triflate ytterbium) in nature. Acids are useful in catalytic or stoichiometric quantities to facilitate chemical reactions. The bases are any basic chemical, which can be inorganic (for example, sodium bicarbonate, potassium hydroxide) or organic (for example, triethylamine, pyridine) in nature. The bases are useful in catalytic or stoichiometric quantities to facilitate chemical reactions.
[000224] In addition, some of the compounds of this invention have one or more double bonds, or one or more asymmetric centers. Such compounds can occur as racemates, racemic mixtures, single enantiomers, individual diastereomers, diastereomeric mixtures, and cis- or trans- or trans- or E- or Z isomeric forms, and other stereoisomeric forms that can be defined in terms of stereochemistry absolute, as (R) - or (S) -, or as (D) - or (L) - for amino acids. All such isomeric forms of these compounds are expressly included in the present invention. Optical isomers can be prepared from their respective optically active precursors by the procedures described above, or by resolving racemic mixtures. Resolution can be carried out in the presence of a resolving agent, by chromatography or by repeated crystallization or by some combination of these techniques which are known to those skilled in the art. Further details regarding the resolutions can be found in Jacques, and other (s), Enantiomers, Racemates, and Resolutions (John Wiley & Sons, 1981). The compounds of this invention can also be represented in multiple tautomeric forms, in such examples, the invention expressly includes all tautomeric forms of the compounds described herein. When the compounds described here contain olefinic double bonds or other centers of geometric asymmetry, and unless otherwise specified, the compounds are intended to include both geometric E and Z isomers. Also, all tautomeric forms are also intended to be included . The configuration of any carbon-carbon double bond appearing here is selected for convenience only and it is not intended to designate a particular configuration unless the text so states; thus a carbon-carbon double bond described arbitrarily here as it can be cis, trans, or a mixture of the two in any proportion. All such isomeric forms of such compounds are expressly included in the present invention. All crystal forms of the compounds described herein are expressly included in the present invention.
[000225] The synthesized compounds can be separated from a reaction mixture and also purified by a method such as column chromatography, high pressure liquid chromatography, or recrystallization. As can be appreciated by the skilled technician, other methods of synthesizing the compounds of the included formulas will be evident to those skilled in the art. In addition, the various synthetic steps can be carried out in an alternating sequence or in order to provide the desired compounds. In addition, solvents, temperatures, reaction times, etc. outlined here are for illustration purposes only and one skilled in the art will recognize that varying reaction conditions can produce the desired compounds of the present invention. Synthetic chemical transformations and protection group (protection and deprotection) methodologies useful for synthesizing the compounds described here are known in the art and include, for example, those as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989 ); T.W. Greene and P.G.M. Wuts, Protective Groups in Orqanic Synthesis, 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fierer, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions of these.
[000226] The compounds of this invention can be modified by adding various functionalities by means of any synthetic means outlined here to enhance the selective biological properties. Such modifications are known in the art and include those that increase biological penetration into a supplied biological system (eg, blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter the rate of excretion.
[000227] The compounds of the invention are defined here by their chemical structures and / or chemical names. Where a compound is referred to equally by a chemical structure and a chemical name, and the chemical structure and chemical name differ, the chemical structure is determinative of the identity of the compound.
[000228] The description of a chemical group listing in any definition of a variable here includes the definitions of that variable as any single group or combination of the groups listed. The description of a modality for a variable here includes that modality as any single modality or in combination with any other modalities or portions thereof.
[000229] Methods of the Invention
[000230] In one aspect, the invention provides a method of selectively inhibiting HDAC6 over other HDACs in an individual, comprising administering a compound of formula I
or a prodrug, ester or pharmaceutically acceptable salt thereof, where,
[000231] Z is N or CR *, where R * is optionally substituted alkyl, optionally substituted acyl, optionally substituted aryl or optionally substituted heteroaryl;
[000232] ring A is an optionally substituted aryl or an optionally substituted heteroaryl;
[000233] ring B is an optionally substituted aryl or an optionally substituted heteroaryl;
[000234] Ri is (i) H, alkyl, haloalkyl, alkenyl, aryl, arylalkyl, heteroaryl, heterocyclic, carbocyclic, C (O) -R2, C (O) O-R2, or S (O) P, each of which can be optionally replaced; or (ii) when Z is CR *, R1 can be optionally substituted branched alkyl, OR3, OR N (R3) (R3), -CH2CH2OH, OCH2CH2OH, SH, or thio alkoxy;
[000235] or the ring B and Ri can together with the atom to which each is attached, form an optionally substituted heterocyclic, or an optionally substituted heteroaryl;
[000236] or R * and Ri together with the atom to which each is attached, can form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl or optionally substituted heteroaryl ring;
[000237] R is H or an optionally substituted alkyl; or R and 0 ring A can be linked to form a fused bicyclic ring that can be optionally substituted;
[000238] each R2 is independently alkyl, cycloalkyl, hetero-cycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[000239] each R3 is independently alkyl, cycloalkyl, hetero-cycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[000240] n is 4, 5, 6, 7 or 8; and
[000241] foot 0.1, or 2.
[000242] In one embodiment, the compound of formula I has a selectivity for HDAC6 of 5 to 1000 times. In certain embodiments, selectivity for HDAC6 is 10-500 times.
[000243] In another embodiment, the compound of formula I has a selectivity for HDAC6 when tested as described in Example 5 from about 5 to 1000 times. In certain modalities, selectivity for HDAC6 is 10-500 times.
[000244] In another aspect, the invention provides a method of treating an HDAC-6 mediated disease in an individual comprising administering to the individual a compound of formula I
or a prodrug, ester or pharmaceutically acceptable salt thereof, where,
[000245] Z is N or CR *, where R * is optionally substituted alkyl, optionally substituted acyl, optionally substituted aryl or optionally substituted heteroaryl;
[000246] Ring A is an optionally substituted aryl or an optionally substituted heteroaryl;
[000247] Ring B is an optionally substituted aryl or an optionally substituted heteroaryl;
[000248] Ri is (i) H, alkyl, haloalkyl, alkenyl, aryl, arylalkyl, heteroaryl, heterocyclic, carbocyclic, C (O) -R2, C (O) O-R2, or S (O) P, each of which can be optionally replaced; or (ii) when Z is CR *, R1 can be optionally substituted branched alkyl, OR3, or N (R3) (R3), -CH2CH2OH, OCH2CH2OH, SH, or thio alkoxy;
[000249] or ring B and Ri may together with the atom to which each is attached, form an optionally substituted heterocyclic, or an optionally substituted heteroaryl;
[000250] or R * and Ri together with the atom to which each is attached, can form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl or optionally substituted heteroaryl ring;
[000251] R is H or an optionally substituted alkyl; or R and 0 ring A can be linked to form a fused bicyclic ring that can be optionally substituted;
[000252] each R2 is independently alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[000253] each R3 is independently alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[000254] n is 4, 5, 6, 7 or 8; and
[000255] foot 0.1, or 2.
[000256] In one embodiment, the disease is cancer or a proliferating disease.
[000257] In another embodiment, the disease is lung cancer, colon cancer, breast cancer, prostate cancer, liver cancer, pancreatic cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, gastric cancer, breast cancer, pancreatic cancer, glioma, gliobastoma, hepatocellular carcinoma, papillary reindeer carcinoma, squamous cell carcinoma of the head and neck, leukemias, lymphomas, myelomas, and solid tumors.
[000258] In another modality, cancer is multiple myeloma.
[000259] In another embodiment, the disease is Wilson's disease, spinocerebellar ataxia, prion disease, Parkinson's disease, Huntington's disease, amitrophic lateral sclerosis, amyloidosis, Alzheimer's disease, Alexander disease, alcoholic liver disease, cystic fibrosis , Pick's disease, spinal muscular dystrophy or Lewy body dementia.
[000260] In certain modalities, the disease is rheumatoid arthritis, osteoarthritis; rheumatoid spondylitis; psoriasis; post-ischemic perfusion injury; inflammatory bowel disease; chronic inflammatory lung disease, eczema, asthma, psoriasis, ischemic / reperfusion injury, ulcerative colitis, acute respiratory distress syndrome, psoriatic arthritis, infectious arthritis, progressive chronic arthritis, deformed arthritis, osteoarthritis, traumatic arthritis, gouty arthritis, syndrome Reiter's disease, polychondritis, spondylitis and acute synovitis, glomerulonephritis, hemolytic anemia, aplastic anemia, idiopathic thrombocytopenia, neutropenia, ulcerative colitis, Crohn's disease, graft versus host disease, allograft rejection, chronic thyroiditis, Graves' disease , diabetes, active hepatitis, primary binary cirrhosis, myasthenia gravis, multiple sclerosis (MS), systemic lupus erythematosus, atopic dermatitis, contact dermatitis, sun skin burns, chronic kidney failure, Stevens-Johnson syndrome, idiopathic sprue, sar - coidosis, Guillain-Barre syndrome, uveitis, conjunctivitis, keratoconjunctivitis, otitis media, periodontal disease, fibrosis int pulmonary interstitial, asthma, bronchitis, rhinitis, sinusitis, pneumoconiosis, pulmonary insufficiency syndrome, pulmonary emphysema, pulmonary fibrosis, silicosis, or chronic inflammatory lung disease.
[000261] In other respects, the invention provides a method of treating an individual suffering from or susceptible to multiple myeloma comprising administering to an individual in need thereof a therapeutically effective amount of a compound of formula I,
or a prodrug, ester or pharmaceutically acceptable salt thereof, where,
[000262] Z is N or CR *, where R * is optionally substituted alkyl, optionally substituted acyl, optionally substituted aryl or optionally substituted heteroaryl;
[000263] ring A is an optionally substituted aryl or an optionally substituted heteroaryl;
[000264] ring B is an optionally substituted aryl or an optionally substituted heteroaryl;
[000265] Ri is (i) H, alkyl, haloalkyl, alkenyl, aryl, arylalkyl, heteroaryl, heterocyclic, carbocyclic, C (O) -R2, C (O) O-R2, or S (O) P, each of which can be optionally replaced; or (ii) when Z is CR *, R1 can be optionally substituted branched alkyl, OR3, OR N (R3) (R3), -CH2CH2OH, OCH2CH2OH, SH, or thio alkoxy;
[000266] or ring B and Ri can together with the atom to which each is attached, form an optionally substituted heterocyclic, or an optionally substituted heteroaryl;
[000267] or R * and Ri together with the atom to which each is attached, can form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl or optionally substituted heteroaryl ring;
[000268] R is H or an optionally substituted alkyl; or R and 0 ring A can be linked to form a fused bicyclic ring that can be optionally substituted;
[000269] each R2 is independently alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[000270] each R3 is independently alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[000271] n is 4, 5, 6, 7 or 8; and
[000272] foot 0.1, or 2;
[000273] to thereby treat the individual suffering from or susceptible to multiple myeloma.
[000274] In various embodiments, the invention provides a method also comprising co-administering one or more of a chemotherapeutic agent, radiation agent, hormonal agent, biological agent or an anti-inflammatory agent to the individual.
[000275] In another embodiment, the chemotherapeutic agent is tamoxifen, trastuzamab, raloxifene, doxorubicin, fluorouracil / 5-fu, disodium pamidronate, anastrozole, exemestane, cyclophosphamide, epirubicin, letrozole, toremifene, fulvastone, fulvestrone, fulvastone, fulvastone, fulvestrone, fulvastone, fulvastone, fulvastone, fulvastone, fulvastone, fulvastone. , megastrol acetate, docetaxel, paclitaxel, testolactone, aziridine, vinblastine, capecitabine, goselerin acetate, zedronic acid, taxol, vinblastine, or vincristine.
[000276] In another embodiment, the invention provides a method in which the individual is a human being.
[000277] In another aspect, the invention provides a kit comprising a compound capable of inhibiting HDAC activity selected from one or more compounds of formula I
or a prodrug, ester or pharmaceutically acceptable salt thereof, where,
[000278] Z is N or CR *, where R * is optionally substituted alkyl, optionally substituted acyl, optionally substituted aryl or optionally substituted heteroaryl;
[000279] ring A is an optionally substituted aryl or an optionally substituted heteroaryl;
[000280] ring B is an optionally substituted aryl or an optionally substituted heteroaryl;
[000281] Ri is (i) H, alkyl, haloalkyl, alkenyl, aryl, arylalkyl, heteroaryl, heterocyclic, carbocyclic, C (O) -R2, C (O) O-R2, or S (O) P, each of which can be optionally replaced; or (ii) when Z is CR *, R1 can be optionally substituted branched alkyl, OR3, OR N (R3) (R3), -CH2CH2OH, OCH2CH2OH, SH, or thio alkoxy;
[000282] or the ring B and Ri can together with the atom to which each is attached, form an optionally substituted heterocyclic, or an optionally substituted heteroaryl;
[000283] or R * and Ri together with the atom to which each is attached, can form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl or optionally substituted heteroaryl ring;
[000284] R is H or an optionally substituted alkyl; or R and 0 ring A can be linked to form a fused bicyclic ring that can be optionally substituted;
[000285] each R2 is independently alkyl, cycloalkyl, hetero-cycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[000286] each R3 is independently alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted;
[000287] n is 4, 5, 6, 7 or 8; and
[000288] foot 0.1, or 2;
[000289] and instructions for use in the treatment of multiple myeloma.
[000290] As discussed above, the present invention provides compounds useful for the treatment of various diseases. In certain embodiments, the compounds of the present invention are useful as inhibitors of histone or tubulin deacetylases and thus are useful as anti-cancer agents, and thus can be useful in the treatment of cancer, by carrying out the death of the tumor cell or inhibiting the development of tumor cells. In certain exemplary embodiments, the inventive anticancer agents are useful in the treatment of cancers and other proliferative disorders, including, but not limited to breast cancer, cervical cancer, colon and rectal cancer, leukemia, lung cancer, melanoma, multiple myeloma, non-Hodgkin's lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, and gastric cancer, to name a few. In certain embodiments, the inventive anticancer agents are active against leukemia cells and melanoma cells, and thus are useful for the treatment of leukemias (for example, myeloid, lymphocytic, myelocytic and lymphoblastic leukemias) and malignant melanomas. In certain embodiments, the compounds are useful in the treatment of multiple myeloma.
[000291] The compounds of the invention are especially effective for treating or preventing inflammatory, immune and autoimmune diseases including, but not limited to, arthritic conditions, such as rheumatoid arthritis, osteoarthritis; rheumatoid spondylitis; psoriasis; post-ischemic perfusion injury; inflammatory bowel disease; chronic inflammatory lung disease, eczema, asthma, psoriasis, ischemic injury / reperfusion, ulcerative colitis, acute respiratory distress syndrome, psoriatic arthritis, infectious arthritis, progressive chronic arthritis, deformed arthritis, osteoarthritis, traumatic arthritis, gouty arthritis, syndrome Reiter's disease, polychondritis, spondylitis and acute synovitis, glomerulonephritis (with or without nephrotic syndrome), autoimmune hematological disorders (eg hemolytic anemia, aplastic anemia, idiopathic thrombocytopenia and neutropenia), autoimmune gastritis and autoimmune inflammatory bowel disease ( for example ulcerative colitis and Crohn's disease), host versus graft disease, allograft rejection, chronic thyroiditis, Graves' disease, scleroderma, diabetes (type I and type II), active hepatitis (acute and chronic), primary cirrhosis binary, severe myasthenia, multiple sclerosis (MS), systemic lupus erythematosus, atopic dermatitis, contact dermatitis, sunburn on the skin, i chronic renal failure, Stevens-Johnson syndrome, idiopathic sprue, sarcoidosis, Guillain-Barre syndrome, uveitis, conjunctivitis, cephoroconjunctivitis, otitis media, periodontal disease, pulmonary interstitial fibrosis, asthma, bronchitis, rhinitis, sinusitis, pneumoconiosis, syndrome pulmonary insufficiency, pulmonary emphysema, pulmonary fibrosis, silicosis, chronic inflammatory lung disease (eg, chronic obstructive pulmonary disease) and other inflammatory or obstructive airway diseases.
[000292] In addition, the inventive compounds may also be useful in the treatment of protozoal infections. The inventive compounds are also useful in the treatment of diseases associated with abnormal protein catabolism, for example, protein degradation disorders, disorders associated with poorly duplicated proteins, and protein deposition disorders. In certain embodiments, the compound is useful in the treatment of protein deposition disorders, Wilson's disease, spinocerebellar ataxia, prion disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, spinal and bulbar muscle atrophy, amyloidosis, Alzheimer's disease, Alexander's disease, alcoholic liver disease, cystic fibrosis, Pick's disease, and Lewy body dementia. In certain exemplary embodiments, the compounds of the invention are useful for disorders associated with histone deacetylation activity. In certain exemplary embodiments, the compounds of the invention are useful for disorders associated with tubulin deacetylation activity.
[000293] Neurodegenerative diseases that can be treated or prevented include Alzheimer's disease, Parkinson's disease, cerebral ischemia, traumatic neurodegenerative disease, chorea or Huntington's disease, senile dementia, memory disorders, vascular dementia, injuries associated with ischemia (stroke) and cranial and spinal trauma, among others.
[000294] The methods outlined here include those in which the individual is identified as in need of a particular specified treatment. The identification of an individual in need of such treatment can be in the judgment of an individual or a healthcare professional and can be subjective (eg, opinion) or objective (eg, measured by a test or diagnostic method).
[000295] As discussed above, the compounds of the invention are selective inhibitors of HDAC6 and, as such, are useful in the treatment of disorders modulated by histone deacetylases. As discussed above, the compounds of the invention are selective inhibitors of tubulin deacetylases and, as such, are useful in the treatment of disorders modulated by tubulin deacetylases. For example, the compounds of the invention may be useful in the treatment of cancer (for example, breast cancer, prostate cancer, multiple myeloma, leukemia, lymphoma, etc.). Consequently, in yet another aspect, according to the treatment methods of the present invention, tumor cells are killed, or their development is inhibited by contacting said tumor cells with an inventive composition or compound, as described herein.
[000296] Thus, in another aspect of the invention, methods for treating cancer are provided comprising administering a therapeutically effective amount of an inventive compound (i.e., of any of the included formulas), as described herein, to an individual in need of this. In certain modalities, the individual is identified as in need of such treatment. In certain embodiments, a method for treating cancer is provided comprising administering a therapeutically effective amount of an inventive compound, or a pharmaceutical composition comprising an inventive compound to an individual in need thereof, in such amounts and for such time as is necessary for achieve the desired result. In certain embodiments of the present invention, a "therapeutically effective amount" of the inventive compound or pharmaceutical composition is that amount effective to kill or inhibit the growth of tumor cells. The compounds and compositions, according to the method of the present invention, can be administered using any amount and any effective administration routine to kill or inhibit the growth of tumor cells. Thus, the term "effective amount to kill or inhibit tumor cell development," as used herein, refers to a sufficient amount of agent to kill or inhibit tumor cell development. The exact amount required will vary from individual to individual, depending on the species, age, and general condition of the individual, the severity of the infection, the particular anticancer agent, its method of administration, and the like).
[000297] In certain embodiments, the method involves administering a therapeutically effective amount of the compound or a pharmaceutically acceptable derivative thereof to an individual (including, but not limited to, a human or animal) in need thereof. In certain embodiments, the inventive compounds are useful for the treatment of cancer (including, but not limited to, glioblastoma, retinoblastoma, breast cancer, cervical cancer, colon and rectal cancer, leukemia (eg, CML, AML, CLL, ALL), lymphoma, lung cancer (including, but not limited to, small cell lung cancer), melanoma and / or skin cancer, multiple myeloma, non-Hodgkin's lymphoma, ovarian cancer, pancreatic cancer, cancer prostate and gastric cancer, bladder cancer, uterine cancer, kidney cancer, testicular cancer, stomach cancer, brain cancer, liver cancer, or esophageal cancer).
[000298] In certain embodiments, the inventive anticancer agents are useful in the treatment of cancers and other proliferative disorders, including, but not limited to, breast cancer, cervical cancer, colon and rectal cancer, leukemia, lung cancer, melanoma, multiple myeloma, non-Hodgkin's lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, and gastric cancer, to name a few. In certain embodiments, the inventive anticancer agents are active against leukemia cells and melanoma cells, and are thus useful for the treatment of leukemias (for example, myeloid, lymphocytic, myelocytic and lymphoblastic leukemias) and malignant melanomas. In yet other embodiments, the inventive anticancer agents are active against solid tumors.
[000299] Multiple myeloma (MM) is a plasma cell malignancy that remains incurable despite conventional treatment (Gregory, and others (1992) J Clin Oncol 10, 334-342) as well as high dose therapy and stem cell transplantation (Attal, M., and other (s) (2003) N Engl J Med 349, 2495-2502). New agents have recently been developed that target not only MM cells, but also the bone marrow (BM) microenvironment, and can overcome the resistance of conventional drugs (Hideshima, T. & Anderson, KC (2002) Nat Rev Câncer 2, 927 -937). For example, the proteasome inhibitor bortezomib (formally PS-341) induces significant antitumor activity in human MM cell lines and MM cells from newly isolated patients (Hideshima, T. & Anderson, KC (2002) Nat Rev Cancer 2, 927-937; Hideshima, and other (2001) Cancer Res. 61, 3071-3076; Mitsiades, N., and other (2002) Proc Natl Acad Sci USA 99, 14374-14379; Hideshima , T., and other (2002) J Biol Chem 277, 16639-47; Mitsiades, N., and other (2003) Blood 101, 2377-80; Chauhan, D., and other (s) ) (2003) Cancer Res 63, 6174-6177; Hideshima, T., and other (2003) Blood 101, 1530-1534; Hideshima, T., and other (2003) Oncogene 22, 8386- 8393; Hideshima, T., and other (2004) Oncogene 23, 8766-8776) associated with c-Jun NH2 terminal kinase (JNK) (also known as stress-activated protein kinase) and activation of caspase, followed by apoptosis (Hideshima, T., and other (2001) Cancer Res. 61, 3071-3076; Mitsiades, N., and other (2002) Proc Natl Acad S ci USA 99, 14374-14379; Hideshima, T., and other (2003) Blood 101, 1530-1534). Bortezomib also inhibits the adherence of MM cells to bone marrow stromal cells (BMSCs) by sub-regulating the adhesion molecules (ICAM-I and VCAM-I) (Hideshima, T., and others (s) ( 2001) Oncogene 20, 4519-4527); as well as inducing cleavage of the catalytic subunit DNA-protein kinase and ataxia mutated telangiectasia, suggesting that bortezomib also inhibits DNA repair. Neither IL-6 nor the adherence of MM cells to BMSCs protects against bortezomib-induced apoptosis. Without wishing to be bound by any scientific theory, bortezomib enhances sensitivity and can overcome resistance in MM cells to conventional chemotherapeutic agents, especially to DNA damaging agents (Mitsiades, N., and others (2003) Blood 101 , 2377-80). In support of this, a phase II trial of treatment of bortezomib of 202 patients with refractory relapsed MM demonstrated 35% responses, including 10% complete and close to complete responses (Richardson, PG, and others (2003) NEngIJMed 348, 2609-2617); however, 65% of patients did not respond. Heat shock protein (hsp) -27 mediates resistance to bortezomib; conversely, inhibiting hsp-27 expression using antisense hsp-27, p38 mitogen-activated protein kinase (MAPK) siRNA, or the MAPK p38 inhibitor for subregular hsp-27 may restore MM cell susceptibility to bortezomib (Chauhan, D., and other (2003) Cancer Res 63, 6174-6177; Hideshima, T., and other (2004) Oncogene 23, 8766-8776).
[000300] In certain embodiments, the inventive compounds also find use in preventing restenosis of blood vessels subjected to trauma such as angioplasty and catheterization. For example, it is contemplated that the compounds of the invention will be useful as a coating for implanted medical devices, such as tubes, bypass, catheters, artificial implants, pins, electrical implants such as pacemakers, and especially for arterial or venous probes, including expandable probes per balloon. In certain embodiments, the inventive compounds can be attached to an implantable medical device, or alternatively, they can be passively absorbed on the surface of the implantable device. In certain other embodiments, the inventive compounds may be formulated to be contained within, or, adapted for release by a surgical or medical device or implant, such as, for example, probes, sutures, catheters, delayed prostheses, and the like (es) ). Consequently, without wishing to be bound by any particular theory, the inventive compounds having antiproliferative effects can be employed as probe coatings and / or in drug delivery devices by probe, inter alia for the prevention of restenosis or reduction of the rate of restenosis. Suitable coatings and general preparation for coated implantable devices are described in United States Patent 6,099,562; 5,886,026; and 5,304,121; each of which is incorporated here by reference. Coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polyethylisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof. The coatings can optionally also be covered with a suitable top coat of fluorosilicone, polysaccharides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics to the composition. A variety of compositions and methods related to probe coating and / or drug delivery by local probe to prevent restenosis are known in the art (see, for example, United States Patent Nos: 6,517,889; 6,273,913; 6,258. 121; 6,251,136; 6,248,127; 6,231,600; 6,203,551; 6,153,252; 6,071,305; 5,891,507; 5,837,313 and published United States patent application No.: US2001 / 0027340, each of which is incorporated herein by reference in its entirety). For example, the probes can be coated with polymer drug conjugates by immersing the probe in the polymer drug solution or by spraying the probe with such a solution. In certain embodiments, materials suitable for the implantable device include biocompatible and non-toxic materials, and may be selected from metals such as nickel-titanium alloys, steel, or biocompatible polymers, hydrogels, polyurethanes, polyethylenes, ethylene vinyl acetate copolymers, etc. In certain embodiments, the inventive compound is coated in a probe for insertion into an artery or vein after balloon angioplasty.
[000301] The compounds of this invention or the pharmaceutically acceptable compositions thereof can also be incorporated into the compositions for coating implantable medical devices, such as prostheses, artificial valves, vascular grafts, probes and catheters. Accordingly, the present invention, in another aspect, includes a composition for coating an implantable device comprising a compound of the present invention as generally described above, and a suitable vehicle for coating said implantable device. In yet another aspect, the present invention includes an implantable device coated with a composition comprising a compound of the present invention as generally described above, and a vehicle suitable for coating said implantable device.
[000302] Within other aspects of the present invention, methods are provided to expand the lumen of a body passage, comprising inserting a probe into the passage, the probe having a generally tubular structure, the surface of the structure being coated with (or another form adapted for release) an inventive compound or composition, such that the passage is expanded. In certain modalities, the lumen of a body passage is expanded in order to eliminate a biliary, gastrointestinal, esophageal, tracheal / bronchial, urethral and / or vascular obstruction.
[000303] In certain embodiments, the invention provides a method of treating any disorders described herein, wherein the individual is a human being.
[000304] According to the foregoing, the present invention also provides a method for preventing or treating any of the diseases or disorders described above in an individual in need of such treatment, which method comprises administering to said individual a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof. For any of the above uses, the required dosage will vary depending on the method of administration, the particular condition to be treated and the desired effect. Pharmaceutical Compositions
[000305] In another aspect, the invention provides a pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable prodrug, salt or ester thereof, together with a pharmaceutically acceptable carrier.
[000306] The compounds of the invention can be administered as pharmaceutical compositions by any conventional routine, in particular enterally, for example, orally, for example, in the form of tablets or capsules, or parenterally, for example, in the form of suspensions or injectable solutions. topically, for example, in the form of lotions, gels, ointments or creams, or in a nasal or suppository form. Pharmaceutical compositions comprising a compound of the present invention in free form or in the form of a pharmaceutically acceptable salt in association with at least one pharmaceutically acceptable carrier or diluent can be manufactured in a conventional manner by mixing, granulating or coating methods. For example, oral compositions can be tablets, or gelatin capsules comprising the active ingredient together with a) diluents, for example, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine; b) lubricants, for example, silica, talc, stearic acid, its magnesium or calcium salt and / or polyethylene glycol; for tablets also c) binders, for example, magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and or polyvinylpyrrolidone; if desired d) disintegrants, for example, starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and / or e) absorbents, colorants, flavors and sweeteners. Injectable compositions can be suspensions or aqueous isotonic solutions and suppositories can be prepared from suspensions or fatty emulsions. The compositions can be sterilized and / or contain adjuvants, such as preservatives, stabilizers, humectants or emulsifiers, solution promoters, salts to regulate osmotic pressure and / or buffers. In addition, they may also contain other therapeutically valuable substances. Formulations suitable for transdermal applications include an effective amount of a compound of the present invention with a vehicle. A vehicle may include absorbable pharmaceutically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a support member, a reservoir containing the compound optionally with vehicles, optionally a rate control barrier to release the compound to the host's skin at a controlled and predetermined rate over a period of time. extended period of time, and means for securing the device to the skin. Matrix transdermal formulations can also be used. Formulations suitable for topical application, for example, to the skin and eyes, are preferably aqueous solutions, ointments, creams or gels well known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
[000307] The compounds of the invention can be administered in therapeutically effective amounts in combination with one or more therapeutic agents (pharmaceutical combinations). For example, synergistic effects can occur with other antiproliferative, anti-cancer, immunomodulatory or anti-inflammatory substances. Where the compounds of the invention are administered in conjunction with other therapies, the dosages of the co-administered compounds will, of course, vary depending on the type of co-drug employed, the specific drug employed, the condition being treated, and so on.
[000308] The combination therapy includes the administration of the object compounds in another combination with other biologically active ingredients (such as, but not limited to, a second and different antineoplastic agent) and non-drug therapies (such as, but not limited to) limited to, radiation treatment or surgery). For example, the compounds of the invention can be used in combination with other pharmaceutically active compounds, preferably compounds that are capable of enhancing the effect of the compounds of the invention. The compounds of the invention can be administered simultaneously (as a single preparation or separate preparation) or sequentially to another drug therapy. In general, a combination therapy aims to administer two or more drugs during a single cycle or course of therapy.
[000309] In certain embodiments, these compositions optionally also comprise one or more additional therapeutic agents. Alternatively, a compound of this invention can be administered to a patient in need of it in combination with the administration of one or more other therapeutic agents. For example, additional therapeutic agents for joint administration or inclusion in a pharmaceutical composition with a compound of this invention may be an approved chemotherapeutic agent, or they may be any one of a number of agents undergoing approval by the Food and Drug Administration that has recently been approved for the treatment of protozoal infections and / or any disorder associated with cellular hyperproliferation. In certain other embodiments, the additional therapeutic agent is an anticancer agent, as discussed in more detail here. In certain other embodiments, the compositions of the invention are useful for the treatment of protozoal infections. In the treatment of cancer or protein degradation disorders, the inventive compound can be combined with a proteasome inhibitor (for example, bortezomib, RI 15777 FTI, MG132, NPI-0052, etc.). In the treatment of cancer or protein degradation disorders, the inventive compound can be combined with a protein degradation inhibitor (for example, another inventive compound, a tubacin-like compound, bortezomib, RI 15777 FTI, MGI 32, NPI-0052, SAHA , 166Ho-DOTMP, arsenic trioxide, 17-AAG, MG 132, etc.).
[000310] It will also be appreciated that the pharmaceutical compounds and compositions of the present invention can be used in combination therapies, that is, the pharmaceutical compounds and compositions can be administered concurrently with, before, or subsequent to, one or more other desired therapies. or medical procedures. The particular combination of therapies (therapies or procedures) to be employed in a combination regimen will take into account the compatibility of the desired therapies and / or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed can achieve a desired effect for the same disorder (for example, an inventive compound can be administered concurrently with another anti-cancer agent), or they can achieve different effects (for example, control of any adverse effects).
[000311] The present invention encompasses pharmaceutically acceptable topical formulations of the inventive compounds. The term "topically pharmaceutically acceptable formulation," as used herein, means any formulation that is pharmaceutically acceptable for intradermal administration of a compound of the invention by applying the formulation to the epidermis. In certain embodiments of the invention, the topical formulation comprises a carrier system. Pharmaceutically effective carriers include, but are not limited to, solvents (e.g., alcohols, polyalcohols, water), creams, lotions, ointments, oils, plasters, liposomes, powders, emulsions, microemulsions, and buffered solutions (for example , buffered saline or hypotonic) or any other vehicle known in the art to topically administer pharmaceuticals. A more complete listing of vehicles known in the art is provided by reference texts that are standard in the art, for example, Remington's Pharmaceutical Sciences, 16th Edition, 1980 and 17th Edition, 1985, both published by Mack Publishing Company, Easton, Pa., the descriptions which are incorporated herein by reference in their entirety. In certain other embodiments, the topical formulations of the invention may comprise excipients. Any pharmaceutically acceptable excipient known in the art can be employed to prepare the inventive pharmaceutically acceptable topical formulations. Examples of excipients that can be included in the topical formulations of the invention include, but are not limited to, preservatives, antioxidants, wetting agents, emollients, buffering agents, solubilizing agents, other penetrating agents, skin protectors, surfactants, and pro - pellets, and / or additional therapeutic agents used in combination with the inventive compound. Suitable preservatives include, but are not limited to, alcohols, quaternary amines, organic acids, parabens, and phenols. Suitable antioxidants include, but are not limited to, ascorbic acid and its esters, sodium bisulfide, butylated hydroxytoluene, butylated hydroxyanisole, tocopherols, and chelating agents and citric acid type EDTA. Suitable humectants include, but are not limited to, glycerin, sorbitol, polyethylene glycols, urea, and propylene glycol. Buffering agents suitable for use with the invention include, but are not limited to, citric, hydrochloric and lactic acid buffers. Suitable solubilizing agents include, but are not limited to, quaternary ammonium chlorides, cyclodextrins, benzyl benzoate, lecithin, and polysorbates. Suitable skin protectors that can be employed in the topical formulations of the invention include, but are not limited to, vitamin E oil, alatoin, dimethicone, glycerin, petroleum and zinc oxide.
[000312] In certain embodiments, the pharmaceutically acceptable topical formulations of the invention comprise at least one compound of the invention and a penetration enhancing agent. The choice of the topical formulation will depend on several factors, including the condition to be treated, the physicochemical characteristics of the inventive compound and other excipients present, its stability in the formulation, available manufacturing equipment, and cost limitations. As used herein, the term "penetration enhancing agent" means an agent capable of transporting a pharmacologically active compound through the stratum corneum and into the epidermis the dermis, preferably with little or no systemic absorption. A wide variety of compounds have been evaluated for their effectiveness in enhancing the rate of drug penetration through the skin. See, for example, Percutaneous Penetration Enhancers, Maibach H. I. and Smith H. E. (eds.), CRC Press, Inc., Boca Raton, Fla. (1995), who studies the use and testing of various skin penetration enhancers, and Buyuktimkin and others, Chemical Means of Transdermal Drug Permeation Enhancement in Transdermal and Topical Drug Delivery Systems, Gosh TK, Pfister WR, Yum SI ( Eds.), Interpharm Press Inc., Buffalo Grove, UI. (1997). In certain exemplary embodiments, penetrating agents for use with the invention include, but are not limited to, triglycerides (eg soy oil), aloe vera compositions (eg aloe vera gel), ethyl alcohol, isopropyl alcohol, octoliphenylpolyethylene glycol, oleic acid, polyethylene glycol 400, propylene glycol, N-decylmethyl sulfoxide. Fatty acid esters (eg, isopropyl myristate, methyl laurate, glycerol monooleate, and propylene glycol monooleate) and N-methyl pyrrolidine.
[000313] In certain embodiments, the compositions can be in the form of ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or plasters. In certain exemplary embodiments, the formulations of the compositions according to the invention are creams, which can also contain saturated or unsaturated fatty acids such as stearic acid, palmitic acid, oleic acid, palmitooleic acid, cetyl or oleyl alcohols , stearic acid being particularly preferred. The creams of the invention may also contain a nonionic surfactant, for example, polyoxy-40-stearate. In certain embodiments, the active component is mixed under sterile conditions with a pharmaceutically acceptable carrier and any necessary preservatives or buffers as may be required. The ophthalmic formulation, ear drops and eye drops are also contemplated to be within the scope of this invention. In addition, the present invention contemplates the use of transdermal patches, which have the additional advantage of providing the controlled release of a compound to the body. Such dosage forms are prepared by dissolving or dispensing the compound in the medium itself. As discussed above, penetration enhancing agents can also be used to increase the flow of the compound through the skin. The rate can be controlled by providing a rate control membrane or by dispersing the compound in a polymer matrix or gel.
[000314] It will also be appreciated that the compounds and pharmaceutical compositions of the present invention can be formulated and employed in combination therapies, that is, the compounds and pharmaceutical compositions can be formulated with or administered concomitantly with, before, or subsequent to, a or more other desired therapeutic or medical procedures. The particular combination of therapies (therapies or procedures) for use in a combination regimen will take into account the compatibility of the desired therapies and / or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed can achieve a desired effect for the same disorder (for example, an inventive compound can be administered concomitantly with another immunomodulatory agent, anticancer agent, or agent useful for the treatment of psoriasis), or they can achieve effects (for example, control of any adverse effects).
[000315] For example, other therapies or anticancer agents that can be used in combination with the inventive compounds of the present invention include, but are not limited to, surgery, radiation therapy (in only a few examples, gamma radiation, neutron beam radiation therapy, radiation therapy) electron beam, proton therapy, brachytherapy, and systemic radioactive isotopes, to designate some) endocrine therapy, biological response modifiers (interferons, interleukins, antibodies, aptamers, siRNAs, oligonucleotides, enzyme, ion channel and receptor inhibitors or activators to name a few), hyperthermia and cryotherapy, agents to mitigate any adverse effects (eg antiemetics), and other approved chemotherapeutic drugs, including, but not limited to, alkylating drugs (eg, mecloretamine, chlorambucil, cyclophosphamide , Melfalan, Ifosfamide), antimetabolites (for example, Methotrexate), purine antagonists and pi antagonists rimidine (for example, 6- Mercaptopurine, 5-Fluorouracil, Cytarabyl, Gemcitabine), spindle poisons (for example, Vinblastine, Vincristine, Vinorelbine, Paclitaxel), polyphototoxins (for example, Etoposide, Irinotecan, Topotecan), antibiotics Doxorubicin, Bleomycin, Mitomycin), nitrosoureas (for example, Carmustine, Lomustine), inorganic ions (for example, Cystopine, Carboplatin), enzymes (for example, Asparaginase), and hormones (for example, Tamoxifen, Leuprolide, Flutamide, and Megestrol), to name a few. For a more comprehensive discussion of updated cancer therapies see, The Merck Manual, seventeenth edition 1999, the total contents of which are incorporated here by reference. See also the National Cancer Institute (CNI) website (www.nci.nih.gov) and the Food and Drug Administration (FDA) website for a list of FDA approved oncology drugs (www.fda.gov/cder/cancer/dmglistfrarne ).
[000316] In certain embodiments, the pharmaceutical compositions of the present invention also comprise one or more additional therapeutically active ingredients (for example, chemotherapeutic and / or palliative). For the purposes of the invention, the term "palliative" refers to treatment that is focused on relieving the symptoms of a disease and / or side effects of a therapeutic regimen, but is not curative. For example, palliative treatment includes pain relievers, anti-nausea medications, antipyretics, and anti-disease drugs. In addition, chemotherapy, radiotherapy and surgery can all be used palliative (ie, to reduce symptoms without resulting in a cure; for example, to shrink tumors and reduce pressure, bleeding, pain and other symptoms of cancer).
[000317] The present compounds and compositions can be administered together with steroidal and hormonal anti-inflammatory agents, such as, but not limited to, estradiol, conjugated estrogens (e.g. PREMARIN, PREMPRO, and PREMPHASE), estradiol beta 17 , calcitonin-salmon, levothyroxine, dexamethasone, medroxyprogesterone, prednisone, cortisone, flunisolide, and hydrocortisone; non-steroidal anti-inflammatory agents, such as, but not limited to, tramadol, fentanyl, metamizole, ketoprofen, naproxen, nabumetone, ketoralac, tromethamine, loxoprophene, ibuprofen, aspirin, and acetaminophen; anti-TNF-Q antibodies, such as infliximab (REMICADE ™) and etanercept (ENBREL ™).
[000318] The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of a compound of the present invention formulated together with one or more pharmaceutically acceptable carriers. As used herein, the term "pharmaceutically acceptable carrier" means encapsulating material, diluent, liquid, non-toxic, inert or semi-solid solid or auxiliary formulation of any kind. The pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as powders, ointments or drops), buccally, or as a spray or nasal.
[000319] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed oils, peanuts, corn, germ, olive oil, castor and sesame), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and sorbitan fatty acid esters and mixtures thereof. In addition to inert diluents, oral compositions may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
[000320] Injectable preparations, for example, sterile injectable oil or aqueous suspensions can be formulated according to the known technique using suitable wetting or dispersing agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution, suspension or emulsion in a non-toxic parenterally acceptable solvent or diluent, for example, as a solution in 1,3-butanediol. Among the acceptable solvents and vehicles that can be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any soft fixed oil can be used including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
[000321] In order to prolong the effect of a drug, it is often desirable to delay the absorption of the drug by subcutaneous or intramuscular injection. This can be covered by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends on its rate of dissolution which, in turn, may depend on the size of the crystal and crystalline shape. Alternatively, the delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oily vehicle.
[000322] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating vehicles or excipients such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature, however liquids in the body temperature and therefore fuse in the rectum or vaginal cavity and release the active compound.
[000323] Solid compositions of a similar type can also be used as fillers in soft and hard loaded gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like).
[000324] The active compounds can also be in micro-encapsulated form with one or more excipients as mentioned above. Solid dosage forms of tablets, pills, capsules, pills and granules can be prepared with coatings and shells such as enteric coatings, release control coatings and other coatings well known in the pharmaceutical formulation technique. In such solid dosage forms the active compound can be mixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal in practice, additional substances other than inert diluents, for example, tablet lubricants and other tabletting auxiliaries such as microcrystalline cellulose magnesium stearate. In the case of capsules, tablets and pills, the dosage forms can also comprise buffering agents.
[000325] Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or plasters. The active component is mixed under sterile conditions with a pharmaceutically acceptable carrier and any necessary preservatives or buffers as may be required. The ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated to be within the scope of this invention.
[000326] Ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites , silicic acid, talc and zinc oxide, or mixtures thereof.
[000327] Powders and sprays may contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays may additionally contain customary propellants such as chlorofluorohydrocarbons.
[000328] Transdermal patches have the additional advantage of providing controlled release of a compound to the body. Such dosage forms can be prepared by dissolving or dispensing the compound in the medium itself. Absorption enhancers can also be used to increase the flow of the compound through the skin. The rate can be controlled by providing a rate control membrane or by dispersing the compound in a polymer or gel matrix.
[000329] According to the treatment methods of the present invention, disorders are treated or prevented in an individual, such as a human or other animal, by administering to the individual a therapeutically effective amount of a compound of the invention, in such quantities and during such time as necessary to achieve the desired result. The term "therapeutically effective amount" of a compound of the invention, as used herein, means a sufficient amount of the compound to lessen the symptoms of a disorder in an individual. As is well understood in medical techniques, a therapeutically effective amount of a compound of this invention will be in a reasonable benefit / risk ratio applicable to any medical treatment.
[000330] In general, the compounds of the invention will be administered in therapeutically effective amounts by any of the usual and acceptable methods known in the art, separately or in combination with one or more therapeutic agents. A therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the individual, the potency of the compound employed and other factors. In general, satisfactory results are indicated to be obtained systemically at daily dosages of about 0.03 to 2.5 mg / kg by body weight (0.05 to 4.5 mg / m2). A daily dosage indicated in the larger mammal, for example humans, is in the range of about 0.5 mg to about 100 mg, conveniently administered, for example, in divided doses up to four times a day or in a delayed form. Unit dosage forms for oral administration comprise approximately 1 to 50 mg of active ingredient.
[000331] In certain embodiments, a therapeutic amount or dose of the compounds of the present invention can vary from about 0.1 mg / kg to about 500 mg / kg (about 0.18 mg / m2 to about 900 mg / kg) m2), alternatively from about 1 to about 50 mg / kg (about 1.8 to about 90 mg / m2). In general, treatment regimens according to the present invention comprise administering to a patient in need of such treatment from about 10 mg to about 1000 mg of the compound (s) of this invention per day in single doses or multiple. Therapeutic amounts or doses will also vary depending on the administration routine as well as the possibility of co-use with other agents.
[000332] In improving a condition in an individual, maintaining the dose of a compound, composition or combination of this invention can be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, can be reduced, as a function of the symptoms, to a level at which the improved condition is maintained when the symptoms have been alleviated to the desired level, treatment must cease. The individual may, however, require intermittent treatment on a long-term basis for any recurrence of disease symptoms.
[000333] It will be understood, however, that the total daily use of the compounds and compositions of the present invention will be decided by the attending physician within the scope of safe medical diagnosis. The specific inhibitory dose for any particular patient will depend on a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound used; the specific composition employed; the patient's age, body weight, general health, sex and diet; the time of administration, the routine of administration, and the rate of excretion of the specific compound employed; the duration of treatment; drugs used in combination or coincident with the specific compound used; and as well-known factors in medical techniques.
[000334] The invention also provides for pharmaceutical combinations, for example, a kit, comprising a) a first agent which is a compound of the invention as described herein, in the free form or in the form of a pharmaceutically acceptable salt, and b) at least one co-agent. The kit may comprise instructions for its administration to an individual suffering from or susceptible to a disease or disorder.
[000335] The terms "co-administration" or "combined administration" or similar (s) as used herein are intended to cover the administration of selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same administration routine or at the same time.
[000336] The term "pharmaceutical combination" as used here means a product that results from the mixture or combination of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients. The term "fixed combination" means that the active ingredients, for example, a compound of the invention and a co-agent, are both administered to a patient simultaneously in the form of a single dosage or entity. The term "non-fixed combination" means that the active ingredients, for example, a compound of the invention and a co-agent, are both administered to a patient as separate entities simultaneously, concurrently or sequentially without any specific time limit, where such administration provides therapeutically effective levels of the two compounds in the patient's body. The latter also applies to cocktail therapy, for example, the administration of three or more active ingredients.
[000337] Some examples of materials that can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, whey proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, salts zinc, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidine, polyacrylates, waxes, polyethylene-polyoxypropylene blocking polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatine; baby powder; excipients such as cocoa butter and suppository waxes, oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soy oil; glycols; such a propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate, agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water, isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other compatible non-toxic lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, with - preservatives and antioxidants may also be present in the composition, according to the formulator's judgment. Protein kinase inhibitors or pharmaceutical salts thereof can be formulated in pharmaceutical compositions for administration to animals or humans. These pharmaceutical compositions, which comprise an effective amount of the protein inhibitor to treat or prevent a protein kinase-mediated condition and a pharmaceutically acceptable carrier, are another embodiment of the present invention. Examples
[000338] The compounds and processes of the present invention will be better understood with respect to the following examples, which are intended by way of illustration only and not to limit the scope of the invention. Various changes and modifications to the described modalities will be evident to those skilled in the art and such changes and modifications including, without limitation, those relating to the chemical structures, substituents, derivatives, formulations and / or methods of the invention can be made without departing from the spirit of the invention and the scope of the attached claims. The definitions of variables in the structures in the schemas here are commensurable with those of the corresponding positions in the formulas outlined here. Example 1: Synthesis of 2- (diphenylamino) -N- (7- (hydroxyamino) -7-oxo-heptyl) pyrimidine-5-carboxamide
Reaction scheme
Synthesis of Intermediate 2

[000339] A mixture of aniline (3.7 g, 40 mmol), ethyl 2-chloropyrimidine-5-carboxylate 1 (7.5 g, 40 mmol), K2CO3 (11 g, 80 mmol) in DMF (100 ml ) was degassed and stirred at 120 ° C under N2 overnight. The reaction mixture was cooled to room temperature and diluted with EtOAc (200 ml), then washed with saturated brine (200 ml x 3). The organic layer was separated and dried over teSCU, evaporated to dryness and purified by chromatography on silica gel (petroleum ethers / EtOAc = 10/1) to provide the desired product as a white solid (6.2 g, 64%) . Intermediate Synthesis 3

[000340] A mixture of compound 2 (6.2 g, 25 mmol), iodobenzene (6.12 g, 30 mmol), Cul (955 mg, 5.0 mmol), Cs2CO3 (16.3 g, 50 mmol) in TEOS (200 ml) it was degassed and purged with nitrogen. The resulting mixture was stirred at 140 ° C for 14 hours. After cooling to room temperature, the residue was diluted with EtOAc (200 ml) and 95% EtOH (200 ml), NH4F-H2O over silica gel [50 g, pre-prepared by adding NH4F (100 g) in water (1500 ml) for silica gel (500 g, 100-200 mesh)] was added, and the resulting mixture was kept at room temperature for 2 hours, the solidified materials were filtered and washed with EtOAc. The filtrate was evaporated to dryness and the residue was purified by chromatography on silica gel (petroleum ethers / EtOAc = 10/1) to provide a yellow solid (3 g, 38%). Synthesis of Intermediate 4

[000341] 2N NaOH (200 ml) was added to a solution of compound 3 (3.0 g, 9.4 mmol) in EtOH (200 ml). The mixture was stirred at 60 ° C for 30 minutes. After evaporation of the solvent, the solution was neutralized with 2N HCl to provide a white precipitate. The suspension was extracted with EtOAc (2 x 200 ml), and the organic layer was separated, washed with water (2 x 100 ml), brine (2 x 100 ml), and dried over Na2SO4. Removal of the solvent provided a brown solid (2.5 g, 92%). Synthesis of Intermediate 6

[000342] A mixture of compound 4 (2.5 g, 8.58 mmol), aminoeptanate 5 (2.52 g, 12.87 mmol), HATU (3.91 g, 10.30 mmol), DIPEA (4.43 g, 34.32 mmol) was stirred at room temperature overnight. After the reaction mixture was filtered, the filtrate was evaporated to dryness and the residue was purified by chromatography on silica gel (petroleum ethers / EtOAc = 2/1) to provide a brown solid (2 g, 54%). Synthesis of 2- (diphenylamino) -N- (7- (hydroxyamino) -7-oxo-heptyl) pyrimidine-5-carboxamide

[000343] A mixture of compound 6 (2.0 g, 4.6 mmol), sodium hydroxide (2N, 20 ml) in MeOH (50 ml) and DCM (25 ml) was stirred at 0 ° C for 10 minutes . Hydroxylamine (50%) (10 ml) was cooled to 0 ° C and added to the mixture. The resulting mixture was stirred at room temperature for 20 minutes. After removing the solvent, the mixture was neutralized with 1M HCI to provide a white precipitate. The crude product was filtered and purified by pre-HPLC to provide a white solid (950 mg, 48%). Example 2: Synthesis of 4- (2,6-dimethylphenylamino) -N- (7- (hydroxyamino) -7-oxo-heptyl) -N-methylbenzamide
Reaction scheme:
Synthesis of Intermediate 3:

[000344] A bottle with three 100 ml_ necks was equipped with a magnetic stir bar, a pressure equalizing drip funnel, and a reflux condenser connected to a nitrogen flow line. The system was dried with a heat gun at the same time that it was stimulated with dry nitrogen. The reaction vessel was then cooled in a water bath at the same time as a slight positive pressure of nitrogen was maintained. The flask was loaded with hydroxylamine-O-sulfonic acid 2 (8.48 g, 0.075 mol) and 95-97% formic acid (45 ml). A solution of cycloeptanone (5.61 g, 0.05 mol) (Note 3) in 15 ml of 95-97% formic acid was added with stirring over a period of 3 minutes. After the addition was completed, the reaction mixture was heated under reflux for 5 hours and then cooled to room temperature. The reaction mixture was quenched with 75 ml of ice water. The aqueous solution was slowly neutralized to pH 7 with sodium hydroxide QN and extracted with three 100 ml portions of chloroform. The combined organic layers were dried with anhydrous magnesium sulfate. After removing the solvent on a rotary evaporator, the hexahydroazocinone product was purified by distillation to provide 3 (4.6 g 72%), 133-135 ° C / 4 mmHg. Synthesis of Intermediate 4:

[000345] 3 (5.6 g, 44.1 mmol) was combined with barium hydroxide (3.8 g, 26.95 mmol) and water (55 ml). The suspension was heated to 110 ° C for 6 hours then cooled over an ice bath. Carbon dioxide gas was bubbled through the solution for 20 minutes. The suspension was filtered through a pad of celite and the filtrate was concentrated to dryness. The residue was triturated with acetonitrile, collected, rinsed with ether and dried in vacuo to produce 4 as a white solid (6.0 g, 93%). Synthesis of Intermediate 5:

[000346] Thionyl chloride (1.81 ml, 24.8 mmol) was added dropwise with stirring to a cold suspension of 4 (1.8 g, 12.4 mmol) in methanol (30 ml) in a rate in order to maintain the reaction temperature between -5 ° C and -10 ° C. After adding all of the thionyl chloride, the mixture was allowed to warm to room temperature and was allowed to stir overnight. The mixture was then concentrated in vacuo to provide a white solid which was triturated in ether (twice) to produce 2.38 g of 7-aminoeptanoic acid, methyl ester, hydrochloride (1: 1) 5 as a white solid ( 4.8 g, 100%). Synthesis of Intermediate 6:

[000347] To a stirred mixture of 5 (1.67 g, 8.54 mmol), NaBH (AcO) 3 (10.8 g, 51.2 mmol) in 1.2 dichloroethane (50 ml) was added benzaldehyde ( 1.00 g, 9.40 mmol) at room temperature. The resulting solution was stirred at room temperature for 4 hours. 37% HCHO (513 mg, 17.0 mmol) was added dropwise within 1 minute. The resulting solution was stirred at room temperature overnight. The solution was filtered through a pad of celite, and the solid mass was washed with DCM (100 ml). The combined organic layers were evaporated to dryness, and the residue was purified by column chromatography on silica gel (EtOAc) to provide 6 (1.41 g, 62.8%) as a colorless oil. Synthesis of Intermediate 7:

[000348] To a stirred solution of 6 (1.50 g, 5.69 mmol) in 1,2-dichloroethane (20 ml) was added 1-chloroethyl carbonochloride (1.0 g, 6.8 mmol) dropwise drop at 0 ° C within 2 minutes. The resulting solution was stirred at reflux for 10 hours. The solution was evaporated in vacuo, and to the residue was added MeOH (20 ml). The resulting mixture was stirred at reflux for 1 hour. The solution was then evaporated to dryness to provide the crude 7 (1.3 g) as a solid which was used directly during the next reaction without further purification. Synthesis of Intermediate 9:

[000349] A mixture of acid 8 (2.01 g, 10 mmol), amine 7 (2.52 g, 12 mmol), DIPEA (5.17 g, 40 mmol) and HATU (4.561 g, 12 mmol) in DCM (30 ml) was stirred at room temperature for 4 hours. After the reaction mixture was evaporated to dryness, the residue was purified by column chromatography on silica gel (petroleum ethers / EtOAc = 1/1) to provide 9 (2.4 g, 66%) as a white solid . Synthesis of Intermediate 11:

[000350] A mixture of amine 10 (0.84 g, 6.94 mmol), bromide 9 (2.06 g, 5.78 mmol), CS2CO3 (4.52 g, 13.8 mmol), Pd2 (dba ) 3 (64 mg, 0.069 mmol) and Xantphos (81 mg, 0.14 mmol) in toluene (20 ml) was degassed and stirred at 100 ° C overnight. The reaction mixture was cooled to room temperature and filtered through celite. The filtrate was evaporated to dryness and the residue was purified by chromatography on silica gel (petroleum ethers / EtOAc = 1/1) to provide 11 (2.21 g, 96%) as a light yellow oil. Synthesis of 4- (2,6-dimethylphenylamino) -N- (7- (hydroxyamino) -7-oxo-heptyl) - N-methylbenzamide

[000351] A mixture of compound 11 (1.58 g, 4.00 mmol), 2N sodium hydroxide (10 ml, 20 mmol) in MeOH (8 ml) and DCM (60 ml) was stirred at 0 ° C for 10 minutes. 50% aqueous hydroxylamine (7.93 g, 120 mmol) was cooled to 0 ° C and added to the mixture and the resulting mixture was stirred at 0 ° C for about 2 hours. The reaction mixture was neutralized with 2 N HCI to pH 7. After removing the solvent, the residue was extracted with EtOAc (10 ml). The organic layer was washed with water (20 ml), and brine (20 ml), dried over Na2SO4, evaporated in vacuo to provide ACY-161-89 (1.55 g, 98%) as a white solid. Example 3: Synthesis of 2- (2,6-dimethylphenylamino) -N- (7- (hydroxyamino) -7-oxo-heptyl) -N-methylpyrimidine-5-carboxamide
Reaction scheme
Synthesis of Intermediate 2

[000352] A mixture of compound 1 (2 g, 12 mmol), DMAP (1.32 g, 11 mmol) and POCh (20 ml) was heated to reflux for 1.5 hours. After removing the solvent, EA was added to the residue. The pH of the mixture was adjusted to 7 with aqueous NaOH (2M), the organic layer was then separated, washed with brine. After removing the solvent, the residue was extracted with PE and dried over Na2SO4, evaporation of the solvent provided a light yellow solid (1 g, 45%). Intermediate Synthesis 3

[000353] A mixture of aniline (325 mg, 2.68 mmol), compound 2 (500 mg, 2.68 mmol), K2CO3 (370 mg, 2.68 mmol) in DMF (10 ml) was degassed and stirred at 140 ° C overnight. The reaction mixture was cooled to room temperature and filtered. The filtrate was washed with water (2x20 ml) and brine (2x20 ml), extracted with EA. The organic layer was dried over Na2SO4, and evaporated to dryness. The residue was purified by chromatography on silica gel (PE / EA = 5/1) to provide the crude product as a brown oil (320 mg, 44%). Synthesis of Intermediate 4

[000354] 2M NaOH (15 ml) was added to a solution of compound 3 (320 mg, 1.18 mmol) in EtOH (15 ml). The mixture was stirred at 60 ° C for 10 minutes. The solution was neutralized with 2M HCI and extracted with EA (2x60 ml). The organic layer was washed with water (2x20 ml), brine (2x20 ml), and dried over Na2SÜ4. Evaporation of the solvent left a white solid (270 mg, 94%). Synthesis of Intermediate 6

[000355] A mixture of compound 4 (270 mg, 1.11 mmol), compound 5 (231 mg, 1.33 mmol), HATU (506 mg, 1.33 mmol), DIPEA (574 mg, 4.44 mmol) ) in THF (30 ml) was stirred at room temperature overnight. The reaction mixture was filtered. The filtrate was evaporated to dryness and the residue was purified by pre-TLC (PE / EA = 1/2) to provide a brown oil (320 mg, 72%). Synthesis of 2- (2,6-dimethylphenylamino) -N- (7- (hydroxyamino) -7-oxo-heptyl) - N-methylpyrimidine-5-carboxamide

[000356] A mixture of compound 6 (200 mg, 0.50 mmol), NaOH (2M, 2 ml) in MeOH (8 ml) and DCM (4 ml) was stirred at 0 ° C for 10 minutes. Hydroxylamine (0.4 ml) was cooled to 0 ° C and added to the mixture. After the resulting mixture was stirred at room temperature for 20 minutes, the organic solvent was removed in vacuo. The residue was acidified with 1M HCI to pH 7 and extracted with EA. The organic layer was washed with water (2x20 ml), brine (2x20 ml), dried over Na2SO4, evaporated to dryness, and the residue was purified by pre-TLC (DCM / MeOH = 5/1) to provide a brown solid. (106mg, 53%). Example 4: Synthesis of N- (7- (hydroxyamino) -7-oxo-heptyl) -4- (hydroxy-phenylmethyl) benzamide Reaction scheme

[000357] To a solution of 1 (201 mg, 1 mmol) in dry THF (5 ml), n-butyllithium solution (1.6 M in hexane, 1.5 ml) was added dropwise to - 65 ° C. After 5 minutes, a solution of benzophenone (182 mg in 5 ml of dry THF) was added over 10 minutes (exothermic). The mixture was stirred for another 30 minutes at -65 ° C and overnight at room temperature. The reaction mixture was quenched with saturated NH4 Cl (10 ml) and concentrated under reduced pressure. The mixture was acidified to pH 4 with 2N HCI, extracted with ethyl acetate (2 x 10 ml). The organic layer was separated, dried over Na2SO4 and concentrated to dryness. The residue was purified with prep-TLC (DCM / MeOH = 10: 1) to provide compound 2 as a white solid (205 mg, 67%).

[000358] A solution of 2 (150 mg, 0.49 mmol), EDCI (190 mg, 0.98 mmol), HOBt (132 mg, 0.98 mmol) and 3 (190 mg, 0.98 mmol) in THF (10 ml) was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by prep-TLC to provide compound 4 as a yellow oil (124 mg, 56%).

[000359] A solution of 4 (124 mg, 0.27 mmol) in MeOH (5 ml) was treated with NaOH (saturated in MeOH, 1.0 ml) and aqueous NH2OH (50% by weight, 0.55 ml) sequentially and was stirred at room temperature for 30 minutes. The reaction mixture was slowly acidified to 0 pH 6-7 with 2N HCI, and extracted with ethyl acetate (2X5 ml). The organic layer was separated, dried over Na2SO4 and concentrated under reduced pressure to provide the title compound as a yellow solid (111 mg, 90%). Example 5: HDAC enzyme assays
[000360] The test compounds were diluted in DMSO at 50 times the final concentration and a ten-fold three-fold dilution series was made. The compounds were diluted in assay buffer (50 mM HEPES, pH 7.4, 100 mM KOI, 0.001% Tween-20, 0.05% BSA, 20 µM TCEP) to 6 times their final concentration. HDAC enzymes (purchased from BPS Biosciences) were diluted to 1.5 times their final concentration in assay buffer. The tripeptide and trypsin substrate at 0.05 pM final concentration were diluted in assay buffer to 6 times its final concentration. The final enzyme concentrations employed in these assays were 3.3 ng / ml (HDAC1), 0.2 ng / ml (HDAC2), 0.08 ng / ml (HDAC3) and 2 ng / ml (HDAC6). The final substrate concentrations used were 16 pM (HDAC1), 10 nM (HDAC2), 17 pM (HDAC3) and 14 piM (HDAC6). Five µl of compounds and 20 µl of enzyme were added to the wells of a dark opaque 384 well plate in duplicate. The enzymes and the compound were incubated together at room temperature for 10 minutes. Five pd of substrate was added to each well, the plate was shaken for 60 seconds and placed in a Victor 2 microtiter plate reader. Fluorescence development was monitored for 60 minutes and the linear reaction rate was calculated. The IC50 was determined using Graph Pad Prism by adjusting a curve of parameter four. Incorporation by reference
[000361] The contents of all references (including literature references, issued patents, published patent applications, and patent co-patent applications) cited throughout this application are hereby expressly incorporated in their entirety by reference. Unless otherwise defined, all technical and scientific terms used here are in accordance with the meaning commonly known to someone with experience versed in the technique. Equivalents
[000362] Those skilled in the art will recognize, or be able to verify, employing no more than routine experimentation, many equivalents of the specific embodiments of the invention described here. Such equivalents are intended to be covered by the following claims.

权利要求:
Claims (24)
[0001]
1. Compound, characterized by the fact that it presents the formula I:
[0002]
2. Compound according to claim 1, characterized by the fact that ring A is phenyl, naphthyl, anthracenyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, imidazolyl, oxazolyl, furyl, thienyl, thiazolyl, triazolyl , isoxazolyl, quinolinyl, pyrrolyl, pyrazolyl, or 5,6,7,8-tetrahydroisoquinoline, or where ring B is phenyl, naphthyl, anthracenyl, pyridinyl, pyridinyl, pyrazinyl, indolyl, imidazolyl, oxazolyl, furyl , thienyl, thiazolyl, triazolyl, isoxazolyl, quinolinyl, pyrrolyl, pyrazolyl, or 5,6,7,8-tetrahydroisoquinoline; each of which can be optionally substituted by C1-C6 alkyl, C1-Cw aryl, C5-Cw heteroaryl, C3-C8 cycloalkyl, 3 to 7 membered heterocycloalkyl, Ci-Ce haloalkyl, halo, OH, NH2, NHR ”, CN , N3, OR NO2, where R ”is H or C 1 -C 6 alkyl, or where R 1 is OH, C 1 -C alkoxy, NH 2, NH (C 1 -C alkyl), N (C 1 -C 6 alkyl) (C 1 -C 6 alkyl) alkyl), NH-aryl, NH-Cs-Cw heteroaryl, N (C6-Cw aryl) (C6-Cw aryl), N (C6-Cw aryl) (C5-Cw heteroaryl), or N (Cs-Cw heteroaryl) roaryl) (C5-Cw heteroaryl).
[0003]
A compound according to claim 1, characterized in that Ri is H, Ci-Ce alkyl, Ce-Cw aryl, or Cs-Cw heteroaryl, or Ri is OH or Ci-Cβ alkoxy, preferably where Ri is H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, phenyl, naphthyl, pyridinyl, OH or OCH3.
[0004]
Compound according to claim 1, characterized by the fact that the carbonyl and the Z group attached to ring A are arranged for each other, or in which the carbonyl and 0 group Z attached to ring A are disposed by one to the other, or in which the carbonyl and the Z group attached to ring A are arranged ortho to each other.
[0005]
5. Compound according to claim 1, characterized by the fact that it presents formula II:
[0006]
6. Compound according to claim 5, characterized by the fact that Xi, Xz, Xs, and X4 are all CR ', or Y and Xe are N and Xi and X4 are CR, or where X2 ® A3' ° to Yo and Xe are CR 'and Xi and X4 are N, or in QUθ Á2 ~ V 0 N'Xaé S, N or O; X, CR'e X4is absent, or in αue X2, ® ’'' ° 'o P H C1-C6 alkyl, C6-C10 aryl, arylalkyl, or C5- where Ri and n' Cio heteroaryl.
[0007]
Compound according to claim 5, characterized by the fact that ring B is phenyl, pyridinyl, pyrimidinyl, or pyrazine; wherein ring B is optionally substituted by C1-C6 alkyl, C1-C7 aryl, C5-C10 heteroaryl, C3-C8 cycloalkyl, 3- to 7-membered heterocycloalkyl, Ci-Ce haloalkyl, halo, OH, NH2, NHR ”, CN, N3, or NO2.
[0008]
8. Compound according to claim 1, characterized by the fact that it presents formula III:
[0009]
Compound according to claim 8, characterized by the fact that ring B is phenyl, pyridinyl, pyrimidinyl, or pyrazine; wherein ring B is optionally substituted by C 1 -C 6 alkyl, C 1 -C 6 aryl, C 1 -C 6 haloalkyl, halo, OH, NH 2, CN, or NO 2.
[0010]
A compound according to claim 8, characterized by the fact that Ri is H, Ci-Cβ alkyl, Ce-Cw aryl, arylalkyl, Cs-Cw heteroaryl, C (O) -R2, or C (O) O- R2, preferably where R2 is pyridinyl.
[0011]
11. Compound according to claim 1, characterized by the fact that it presents formula IV:
[0012]
12. A compound according to claim 11, characterized by the fact that the B ring is phenyl, pyridinyl, pyrimidinyl or pyrazinyl, wherein the B ring is optionally substituted by C1- C β alkyl, Ce-C ar aryl, Ci-Cβ haloalkyl, halo, OH, NH2, CN, or NO2.
[0013]
A compound according to claim 11, characterized in that Ri is H, Ci-Cβ alkyl, Ce-Cw aryl, arylalkyl, or heteroaryl Cs-Cw, where Ri is optionally substituted by OH or halo.
[0014]
14. The compound according to claim 11, characterized by the fact that the compound of formula IV is:
[0015]
15. A compound according to claim 11, characterized by the fact that the compound of formula IV is:
[0016]
16. A compound according to claim 11, characterized by the fact that the compound of formula IV is:
[0017]
17. A compound according to claim 1, characterized by the fact that the compound of formula VI is:
[0018]
18. Composed according to claim 1, characterized by the fact that it is selected from the following:
[0019]
19. Pharmaceutical composition, characterized in that it comprises a compound as defined in any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
[0020]
A compound according to any one of claims 1 to 18, or the pharmaceutical composition as defined in claim 19, characterized (a) in that it is for use as a medicament.
[0021]
21. Use of a compound as defined in any one of claims 1 to 18 or a pharmaceutical composition as defined in claim 19, characterized in that it is for preparing a medicament for the treatment of cancer or a proliferative disease, preferably in which the disease is cancer lung cancer, colon cancer, breast cancer, prostate cancer, liver cancer, pancreatic cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, gastric cancer, glioma , gliobastoma, hepatocellular carcinoma, papillary renal carcinoma, squamous cell carcinoma of the head and neck, leukemias, lymphomas, myelomas, and solid tumors, or in which the cancer is multiple myeloma.
[0022]
22. Use of a compound as defined in any of claims 1 to 18 or a pharmaceutical composition as defined in claim 19, characterized in that it is for preparing a medicament for the treatment of Wilson's disease, spinocerebellar ataxia, prion disease, Parkinson's disease , Huntington's disease, amitrophic lateral sclerosis, amyloidosis, Alzheimer's disease, Alexander disease, alcoholic liver disease, cystic fibrosis, Pick's disease, spinal muscular dystrophy or Lewy body dementia.
[0023]
23. Use of a compound as defined in any one of claims 1 to 18 or a pharmaceutical composition as defined in claim 19, characterized in that it is for preparing a medicament in the treatment of rheumatoid arthritis, osteoarthritis; rheumatoid spondylitis; psoriasis; post-ischemic perfusion injury; inflammatory bowel disease; chronic inflammatory lung disease, eczema, asthma, psoriasis, ischemic / reperfusion injury, ulcerative colitis, acute respiratory distress syndrome, psoriatic arthritis, infectious arthritis, progressive chronic arthritis, deforming arthritis, osteoarthritis, traumatic arthritis, gouty arthritis, Reiter's syndrome , polychondritis, spondylitis and acute synovitis, glomerulonephritis, hemolytic anemia, aplastic anemia, idiopathic thrombocytopenia, neutropenia, ulcerative colitis, Crohn's disease, host versus graft disease, allograft rejection, chronic thyroiditis, Grave's disease, scleroderma, diabetes , active hepatitis, primary binary cirrhosis, myasthenia gravis, multiple sclerosis (MS), systemic lupus erythematosus, atopic dermatitis, contact dermatitis, sunburn on the skin, chronic kidney failure, Stevens-Johnson syndrome, idiopathic sprue, sarcoidosis, syndrome de Guillain-Barre, uveitis, conjunctivitis, keratoconjunctivitis, otitis media, periodontal disease, interstitial fibrosis pulmonary ial, asthma, bronchitis, rhinitis, sinusitis, pneumoconiosis, pulmonary insufficiency syndrome, pulmonary emphysema, pulmonary fibrosis, silicosis, or chronic inflammatory lung disease.
[0024]
24. Kit characterized by the fact that it comprises a compound capable of inhibiting HDAC activity selected from one or more compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein, Z is N or CR *, where R * is C 1 -C 6 alkyl, acyl, Ce-C 6 aryl or C 5-C 10 heteroaryl; Ring A is Ce-Cw aryl or C5-C10 heteroaryl; Ring B is Ce-Cw aryl or Cs-Cw heteroaryl, where aryl and heteroaryl are optionally substituted by CI-CΘalkyl, Ce-Cw aryl, Ci-Cβ haloalkyl, halo, OH, NH2, CN, or NO2; Ri is (i) H, C1-C6alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C6-Cw aryl, arylalkyl, Cs-Cw heteroaryl, heterocyclic, carbocyclic, C (O) -R2, C (O) O- R2, OR S (O) P; OR (ii) when Z is CR *, Ri can be branched C1-Calkyl, OR3, or N (R3) (Rs), -CH2CH2OH, OCH2CH2OH, SH, or C1 -C6 thio alkoxy; D H or Ci-Cβ alkyl; or R and 0 ring A can be linked to form a fused bicyclic ring; each R2 is independently Ci-Cβ alkyl, C3-C8 cycloalkyl, 3- to 7-membered heterocycloalkyl, Ce-Cw aryl, or Cs-Cw he-teroaryl; each R3 θ independently Ci-Cβ alkyl, C3-C8 cycloalkyl, 3- to 7-membered heterocycloalkyl, Ce-Cw aryl, or Cs-Cw he-teroaryl; n is 4, 5, 6, 7 or 8; ep is 0, 1, or 2, and instructions for use in the treatment of multiple myeloma.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112012018246B1|2020-10-06|REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS, PHARMACEUTICAL COMPOSITION UNDERSTANDING THOSE COMPOUNDS, KIT AND USES OF THE SAME

---

ES2568260T3|2016-04-28|Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof

同族专利:

---

公开号 | 公开日

---

JP2013518050A|2013-05-20|

---

US8394810B2|2013-03-12|

---

PL2526093T3|2017-02-28|

---

KR101808874B1|2018-01-18|

---

CN105727298A|2016-07-06|

---

CN105753739A|2016-07-13|

---

HUE030679T2|2017-05-29|

---

EA026514B1|2017-04-28|

---

EP3091004B1|2017-12-13|

---

TW201141480A|2011-12-01|

---

TWI511732B|2015-12-11|

---

US20110300134A1|2011-12-08|

---

JP2016153425A|2016-08-25|

---

NZ601655A|2014-10-31|

---

US20150045380A1|2015-02-12|

---

US20120190693A1|2012-07-26|

---

CL2012002026A1|2013-01-18|

---

CY1118156T1|2017-06-28|

---

BR112012018246A2|2016-04-05|

---

CN102933558A|2013-02-13|

---

RS55227B1|2017-02-28|

---

US20140142117A1|2014-05-22|

---

SG10201500444TA|2015-03-30|

---

ES2592278T3|2016-11-29|

---

US8148526B1|2012-04-03|

---

SMT201600382B|2017-01-10|

---

EP2526093A4|2014-07-30|

---

US8609678B2|2013-12-17|

---

US20120083504A1|2012-04-05|

---

TW201604177A|2016-02-01|

---

AU2016213729A1|2016-08-25|

---

HRP20161367T1|2016-12-02|

---

EP3091004A1|2016-11-09|

---

SI2526093T1|2016-10-28|

---

DK2526093T3|2016-11-14|

---

US20160375021A1|2016-12-29|

---

CN102933558B|2016-03-16|

---

WO2011091213A3|2011-12-01|

---

TW201735926A|2017-10-16|

---

AU2011207289A1|2012-08-16|

---

KR20120118480A|2012-10-26|

---

US20200030325A1|2020-01-30|

---

CA2787756A1|2011-07-28|

---

LT2526093T|2016-10-10|

---

CA2787756C|2019-06-18|

---

EP2526093B1|2016-08-17|

---

JP5940984B2|2016-06-29|

---

PT2526093T|2016-11-25|

---

WO2011091213A2|2011-07-28|

---

TWI600638B|2017-10-01|

---

SG182646A1|2012-08-30|

---

EA201290677A1|2013-02-28|

---

EP2526093A2|2012-11-28|

---

MX2012008553A|2012-11-30|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US5304121A|1990-12-28|1994-04-19|Boston Scientific Corporation|Drug delivery system making use of a hydrogel polymer coating|

---

US5716981A|1993-07-19|1998-02-10|Angiogenesis Technologies, Inc.|Anti-angiogenic compositions and methods of use|

---

US6231600B1|1995-02-22|2001-05-15|Scimed Life Systems, Inc.|Stents with hybrid coating for medical devices|

---

US6099562A|1996-06-13|2000-08-08|Schneider Inc.|Drug coating with topcoat|

---

US5837313A|1995-04-19|1998-11-17|Schneider Inc|Drug release stent coating process|

---

US6777217B1|1996-03-26|2004-08-17|President And Fellows Of Harvard College|Histone deacetylases, and uses related thereto|

---

ZA9710342B|1996-11-25|1998-06-10|Alza Corp|Directional drug delivery stent and method of use.|

---

US6273913B1|1997-04-18|2001-08-14|Cordis Corporation|Modified stent useful for delivery of drugs along stent strut|

---

US5891507A|1997-07-28|1999-04-06|Iowa-India Investments Company Limited|Process for coating a surface of a metallic stent|

---

US6153252A|1998-06-30|2000-11-28|Ethicon, Inc.|Process for coating stents|

---

US6248127B1|1998-08-21|2001-06-19|Medtronic Ave, Inc.|Thromboresistant coated medical device|

---

US6258121B1|1999-07-02|2001-07-10|Scimed Life Systems, Inc.|Stent coating|

---

US6203551B1|1999-10-04|2001-03-20|Advanced Cardiovascular Systems, Inc.|Chamber for applying therapeutic substances to an implant device|

---

US6251136B1|1999-12-08|2001-06-26|Advanced Cardiovascular Systems, Inc.|Method of layering a three-coated stent using pharmacological and polymeric agents|

---

US20030129724A1|2000-03-03|2003-07-10|Grozinger Christina M.|Class II human histone deacetylases, and uses related thereto|

---

CA2404002A1|2000-03-24|2001-09-27|Methylgene Inc.|Inhibitors of histone deacetylase|

---

US20050119305A1|2001-03-21|2005-06-02|Masao Naka|Il-6 production inhibitors|

---

US7244853B2|2001-05-09|2007-07-17|President And Fellows Of Harvard College|Dioxanes and uses thereof|

---

AT375331T|2001-11-01|2007-10-15|Janssen Pharmaceutica Nv|AMID DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3-BETA|

---

US6517889B1|2001-11-26|2003-02-11|Swaminathan Jayaraman|Process for coating a surface of a stent|

---

US7154002B1|2002-10-08|2006-12-26|Takeda San Diego, Inc.|Histone deacetylase inhibitors|

---

US7169801B2|2003-03-17|2007-01-30|Takeda San Diego, Inc.|Histone deacetylase inhibitors|

---

AU2005230682B2|2004-04-05|2010-10-21|Merck Hdac Research, Llc|Histone deacetylase inhibitor prodrugs|

---

CA2937005A1|2005-03-22|2006-09-28|President And Fellows Of Harvard College|Treatment of protein degradation disorders|

---

JP2009509923A|2005-08-26|2009-03-12|メシルジーン、インコーポレイテッド|Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase|

---

AU2007345292B2|2006-02-14|2013-10-31|Dana-Farber Cancer Institute, Inc.|Bifunctional histone deacetylase inhibitors|

---

CA2654540C|2006-05-03|2017-01-17|President And Fellows Of Harvard College|Histone deacetylase and tubulin deacetylase inhibitors|

---

US20100278782A1|2006-06-12|2010-11-04|Vrije Universiteit Brussel|Differentiation of rat liver epithelial cells into hepatocyte-like cells|

---

ES2288802B1|2006-07-07|2008-12-16|Universidad De Granada|NEW DERIVATIVES OF FTALIMIDA AS INHIBITORS OF HISTONES DESACETILASAS.|

---

EP2061468A4|2006-09-11|2011-05-04|Curis Inc|Tyrosine kinase inhibitors containing a zinc binding moiety|

---

US8119616B2|2007-09-10|2012-02-21|Curis, Inc.|Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety|

---

TWI478709B|2008-02-19|2015-04-01|Earnest Medicine Co Ltd|A useful oral or enteral composition for the recovery of bodily functions|

---

AU2009274549B2|2008-07-23|2014-05-01|Dana-Farber Cancer Institute, Inc.|Deacetylase inhibitors and uses thereof|

---

EP2429987A4|2009-05-15|2012-10-03|Korea Res Inst Chem Tech|Amide compound, preparation method thereof and pharmaceutical composition comprising same|

---

US8716344B2|2009-08-11|2014-05-06|President And Fellows Of Harvard College|Class- and isoform-specific HDAC inhibitors and uses thereof|

---

EP2638009A4|2010-01-08|2014-06-11|Harvard College|Fluorinated hdac inhibitors and uses thereof|

---

KR101808874B1|2010-01-22|2018-01-18|에이스틸론 파마수티컬스 인코포레이티드|Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof|

---

CA2800143A1|2010-05-21|2011-11-24|The Trustees Of Columbia University In The City Of New York|Selective hdac inhibitors|

---

WO2013013113A2|2011-07-20|2013-01-24|The General Hospital Corporation|Histone deacetylase 6 selective inhibitors for the treatment of bone disease|

---

US9663825B2|2012-04-19|2017-05-30|Acetylon Pharmaceuticals, Inc.|Biomarkers to identify patients that will respond to treatment and treating such patients|

---

WO2015054099A1|2013-10-08|2015-04-16|Acetylon Pharmaceuticals, Inc.|Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors|

---

JP6952602B2|2014-07-07|2021-10-20|アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．|Treatment of leukemia with histone deacetylase inhibitors|

---

ES2769255T3|2015-06-08|2020-06-25|Acetylon Pharmaceuticals Inc|Methods for making protein deacetylase inhibitors|

---

EP3368026A1|2015-10-27|2018-09-05|Acetylon Pharmaceuticals, Inc.|Hdac inhibitors for the treatment of diabetic peripheral neuropathy|KR101808874B1|2010-01-22|2018-01-18|에이스틸론 파마수티컬스 인코포레이티드|Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof|

---

WO2012018499A2|2010-08-05|2012-02-09|Acetylon Pharmaceuticals|Specific regulation of cytokine levels by hdac6 inhibitors|

---

AU2011311531B2|2010-10-08|2014-11-20|Life Sciences Research Partners Vzw|HDAC inhibitors to treat Charcot-Marie-Tooth disease|

---

US8614223B2|2010-11-16|2013-12-24|Acetylon Pharmaceuticals, Inc.|Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof|

---

WO2012117421A1|2011-03-02|2012-09-07|Orchid Research Laboratories Ltd|Histone deacetylase inhibitors|

---

FR2975911A1|2011-06-06|2012-12-07|Univ Strasbourg|BISACODYL AND THE LIKE AS MEDICAMENTS FOR THE TREATMENT OF CANCER|

---

WO2013013113A2|2011-07-20|2013-01-24|The General Hospital Corporation|Histone deacetylase 6 selective inhibitors for the treatment of bone disease|

---

KR101359571B1|2011-10-06|2014-02-10|서울대학교산학협력단|Pharmaceutical composition containing histone deacetylase inhibitors and alpha­calcium sulfate as active ingredients for periodontal disease|

---

CA2868302A1|2012-03-23|2013-09-26|Dennis M. Brown|Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo|

---

US9663825B2|2012-04-19|2017-05-30|Acetylon Pharmaceuticals, Inc.|Biomarkers to identify patients that will respond to treatment and treating such patients|

---

US9145412B2|2012-11-02|2015-09-29|Acetylon Pharmaceuticals, Inc.|Selective HDAC1 and HDAC2 inhibitors|

---

WO2015054099A1|2013-10-08|2015-04-16|Acetylon Pharmaceuticals, Inc.|Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors|

---

EP3054954A4|2013-10-10|2017-12-13|Acetylon Pharmaceuticals, Inc.|Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma|

---

WO2015054474A1|2013-10-10|2015-04-16|Acetylon Pharmaceuticals, Inc.|Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors|

---

WO2015054355A1|2013-10-10|2015-04-16|Acetylon Pharmaceuticals, Inc.|Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma|

---

CA2926808A1|2013-10-11|2015-04-16|Acetylon Pharmaceuticals, Inc.|Combinations of histone deacetylase inhibitors and immunomodulatory drugs|

---

EP3060217A4|2013-10-24|2017-04-12|Mayo Foundation for Medical Education and Research|Treatment of polycystic diseases with an hdac6 inhibitor|

---

PE20161030A1|2013-12-03|2016-11-06|Acetylon Pharmaceuticals Inc|COMBINATIONS OF ACETYLASE HISTONE INHIBITORS AND IMMUNOMODULATING DRUGS|

---

US9464073B2|2014-02-26|2016-10-11|Acetylon Pharmaceuticals, Inc.|Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors|

---

CA2941581C|2014-03-12|2018-07-24|Chong Kun Dang Pharmaceutical Corp.|Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same|

---

KR20170003688A|2014-05-14|2017-01-09|더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트|Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof|

---

JP6952602B2|2014-07-07|2021-10-20|アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．|Treatment of leukemia with histone deacetylase inhibitors|

---

EP3226903A1|2014-12-05|2017-10-11|University of Modena and Reggio Emila|Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma|

---

ES2816641T3|2014-12-12|2021-04-05|Regenacy Pharmaceuticals Inc|Piperidine derivatives as HDAC1 / 2 inhibitors|

---

AR103598A1|2015-02-02|2017-05-24|Forma Therapeutics Inc|BICYCLIC ACIDS [4,6,0] HYDROXAMICS AS HDAC INHIBITORS|

---

DK3292116T3|2015-02-02|2022-01-10|Valo Health Inc|3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS|

---

WO2016168647A1|2015-04-17|2016-10-20|Acetylon Pharmaceuticals Inc.|Treatment of neuroblastoma with histone deacetylase inhibotrs|

---

US10421778B2|2015-05-05|2019-09-24|Washington University|Isoform-selective lysine deacetylase inhibitors|

---

BR112017024952A2|2015-05-22|2018-07-31|Chong Kun Dang Pharmaceutical Corp|compounds derived from heterocyclic alkyl as selective histone deacetylase inhibitors and pharmaceutical compositions, comprising the same|

---

US10272084B2|2015-06-01|2019-04-30|Regenacy Pharmaceuticals, Llc|Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy|

---

AR104935A1|2015-06-08|2017-08-23|Acetylon Pharmaceuticals Inc|CRYSTAL FORMS OF A HISTONA DEACETILASA INHIBITOR|

---

ES2769255T3|2015-06-08|2020-06-25|Acetylon Pharmaceuticals Inc|Methods for making protein deacetylase inhibitors|

---

CN104974080A|2015-07-19|2015-10-14|佛山市赛维斯医药科技有限公司|11beta-HSD1inhibitor containing bipyridine tertiary alcohol structure as well as preparation method and application thereof|

---

CN105017135A|2015-07-19|2015-11-04|佛山市赛维斯医药科技有限公司|11 beta-HSD1 inhibitor with dipyridyl-tert-alcohol structure and its preparation method and use|

---

CN104974084A|2015-07-19|2015-10-14|佛山市赛维斯医药科技有限公司|11beta-HSD1inhibitor containing aminobipyridine tertiary alcohol structure and application thereof|

---

EP3328843A4|2015-07-27|2019-01-16|Chong Kun Dang Pharmaceutical Corp.|1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same|

---

ES2774510T3|2015-07-27|2020-07-21|Chong Kun Dang Pharmaceutical Corp|1,3,4-Oxadiazole sulfamide derivatives as histone deacetylase 6 inhibitors and pharmaceutical composition comprising the same|

---

RU2700696C2|2015-07-27|2019-09-19|Чонг Кун Данг Фармасьютикал Корп.|1,3,4-oxadisolamide derivative compound as histone deacetylase 6 inhibitor and pharmaceutical composition containing thereof|

---

KR101799010B1|2015-08-04|2017-11-17|주식회사 종근당|1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same|

---

US10154997B2|2015-08-04|2018-12-18|Washington University|Treatment of parasitic diseases using KDAC inhibitor compounds|

---

EP3368026A1|2015-10-27|2018-09-05|Acetylon Pharmaceuticals, Inc.|Hdac inhibitors for the treatment of diabetic peripheral neuropathy|

---

CA3051354A1|2016-02-16|2017-08-24|The Board Of Trustees Of The University Of Illinois|Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors|

---

AU2017233898A1|2016-03-15|2018-11-01|Oryzon Genomics, S.A.|Combinations of LSD1 inhibitors for use in the treatment of solid tumors|

---

WO2017157813A1|2016-03-15|2017-09-21|F. Hoffmann-La Roche Ag|Combinations of lsd1 inhibitors for the treatment of hematological malignancies|

---

US10555935B2|2016-06-17|2020-02-11|Forma Therapeutics, Inc.|2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors|

---

US20180036306A1|2016-08-08|2018-02-08|Acetylon Pharmaceuticals Inc.|Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and cd20 inhibitory antibodies|

---

WO2018081556A1|2016-10-28|2018-05-03|Acetylon Pharmaceuticals, Inc.|Pharmaceutical combinations comprising a histone deacetylase inhibitor and epothilone and methods of use thereof|

---

WO2018081585A1|2016-10-28|2018-05-03|Acetylon Pharmaceuticals, Inc.|Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof|

---

EP3535275A4|2016-11-04|2020-06-24|Acetylon Pharmaceuticals, Inc.|Pharmaceutical combinations comprising a histone deacetylase inhibitor and a bcl-2 inhibitor and methods of use thereof|

---

JP2020500200A|2016-11-23|2020-01-09|アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．|Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed cell death ligand 1inhibitor and methods of using the same|

---

WO2019083960A1|2017-10-24|2019-05-02|Oncopep, Inc.|Peptide vaccines and hdac inhibitors for treating multiple myeloma|

---

US20210078963A1|2018-01-09|2021-03-18|Shuttle Pharmaceuticals, Inc.|Selective histone deacetylase inhibitors for the treatment of human disease|

---

KR20190099952A|2018-02-20|2019-08-28|주식회사 종근당|Compositions for Preventing or Treating Uveitis|

---

KR102316234B1|2018-07-26|2021-10-22|주식회사 종근당|1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same|

---

CN111943892A|2019-05-17|2020-11-17|上海中泽医药科技有限公司|Histone deacetylase subtype inhibitor thioacetylarylamine compound and application thereof|

---

CA3136223A1|2019-05-31|2020-12-03|Chong Kun Dang Pharmaceutical Corp.|1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same|

---

BR112021023770A2|2019-05-31|2022-01-11|Chong Kun Dang Pharmaceutical Corp|1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor and the pharmaceutical composition comprising the same|

---

KR20210108555A|2020-02-25|2021-09-03|주식회사 종근당|1,3,4-Oxadiazol Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same|

---

KR20210108274A|2020-02-25|2021-09-02|주식회사 종근당|1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same|

---

KR20210126970A|2020-04-13|2021-10-21|주식회사 종근당|1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same|

---

WO2022013728A1|2020-07-14|2022-01-20|Chong Kun Dang Pharmaceutical Corp.|Novel compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same|

法律状态:
2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law|

---

2018-04-10| B06F| Objections, documents and/or translations needed after an examination request according art. 34 industrial property law|

---

2019-05-21| B07E| Notice of approval relating to section 229 industrial property law|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-07-09| B06T| Formal requirements before examination|

---

2019-11-19| B06A| Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law|

---

2020-03-24| B06A| Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law|

---

2020-06-30| B09A| Decision: intention to grant|

---

2020-10-06| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/01/2011, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US33646010P| true| 2010-01-22|2010-01-22|

---

US61/336,460|2010-01-22|

---

PCT/US2011/021982|WO2011091213A2|2010-01-22|2011-01-21|Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof|

---